HALL A
27 November 2022
HALL B
27 November 2022
Session 1: Paediatric Oncology
Dr. Zainul Aabideen | United Arab Emirates

Dr. Zainul Aabideen
Consultant Paediatric | United Arab Emirates
"Dr. Zainul is a highly skilled and experienced in Paediatric Haematology and Oncology. He received his Degree in Medicine at Calicut University in Kerala, India, subsequently he took his Post - Graduate degree in Paediatrics from the University of Mumbai. In 2001, Dr. Zainul moved to the United Kingdom where he specialize and undertake further training and experience in paediatric haematology, paediatric oncology and Paediatric Bone Marrow Transplantation in various hospitals in UK. Dr. Zainul gained his master’s degree in Paediatric Oncology at Birmingham University as well as Certificate in Medical Education at Manchester University. Subsequently, he completed his International Fellowship in Paediatric Bone Marrow Transplantation at Great North Children’s Hospital in Newcastle. He worked previously as Consultant Pediatric at University Hospital of Coventry and Warwickshare and Royal Oldham Hospital before moving to UAE. In the UAE, He had worked at Department of Pediatric hematology and Oncvology Tawam Hospital as Consultant, Al Ain, before he joined at Burjeel Medical City. Aside from his commitment to further advance his experience and knowledge in the field of Paediatrics, Paediatric Haematology, Oncology and Bone Marrow Transplantation in the United Kingdom he also published numerous articles and actively support by sharing his knowledge to the community by participating international conference across countries."
Sessions by this speaker
Thursday,
-
Lectures by this speaker
Thursday,
-
Chairperson:
Dr. Omran El Koha | United Arab Emirates

Dr. Omran El Koha
Consultant Radiation /Clinical Oncologist | United Arab Emirates
Dr. Omran is an experienced clinical oncologist with a demonstrated history of working in the medical and radiation oncology p . Skilled in Clinical Research, Medical Education, Strategic Planning. Strong education professional with a Master's Degree focused in Health research ethics
Sessions by this speaker
Thursday,
-
Thursday,
-
Lectures by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Chairperson:
Dr. Layla Al Reyami | United Arab Emirates

Dr. Layla Al Reyami
Pediatrician | United Arab Emirates
Dr. Layla Al Reyami is a pediatrician at SEHA who graduated from Gulf Medical University.
Sessions by this speaker
Thursday,
-
Speaker:
Dr. Naser Alzein | United Arab Emirates

Dr. Naser Alzein
Chief Division of pediatric hematology/oncology | United Arab Emirates
Dr Naser is currently serving as Chief Division of pediatric hematology/oncology at Sheikh Khalifa Medical City (SKMC). Dr Naser joined SKMC in 2009. Before that, he served as the medical director of pediatric hematology/oncology at Blank Children’s Hospital in Des Moines, Iowa in the United States of America. He is an assistant professor of pediatrics/pediatric hematology/Oncology at Carver College of Medicine at the University of Iowa in the United States. Dr Naser completed his medical school from Jordan University of Science and Technology in Jordan in 1993, and then he did his PhD in Pediatrics at the University of Jordan. Dr Alzein, completed his training in the United States of America. He is double American board certified in Pediatrics and pediatric Hematology/Oncology. Dr Naser has major interest in Lymphoma and hematological malignancies, as well as benign hematology like hemoglobinopathies He is a 2 times winner of the American Society of Oncology (ASCO) Merit Award; for the best translational medicine research abstract in cancer genetic. In addition, he won the Lymphoma Spore Group Grant Award in 2005 for his work on DNA methylation in B cell Lymphomas. In addition, Dr Alzein won 3 times the Best Teaching Award from the Education Department at SKMC Dr Alzein, has great experience in bone marrow transplant and solid tumors as well. Dr Alzein has been a speaker in several International and regional meetings. He has multiple publications related to his field.
Sessions by this speaker
Thursday,
-
Lectures by this speaker
Thursday,
-
Speaker:
Dr. Mohammed Al Nuaimi | United Arab Emirates

Dr. Mohammed Al Nuaimi
Consultant Physician | United Arab Emirates
"Dr. Mohammed Al Nuaimi is a consultant physician in Pediatric Hematology & Oncology, Bone Marrow Transplant and Cellular Therapy, at Tawam Hospital, Al-Ain, UAE. He completed his general pediatrics residency training, pediatric hematology & oncology fellowship & Bone Marrow Transplant and Cellular Therapy fellowship at The Hospital for Sick Children (SickKids) Toronto, Canada. Dr. Al Nuaimi holds the Canadian and American Boards of general pediatrics, and the Canadian board in Pediatric Hematology & Oncology. He has a special interest in bone marrow failure diseases, bone marrow transplant and celluar therapy. Dr. Al Nuaimi is a member of several professional societies including Children's Oncology Group (COG) and American Society of Hematology (ASH). He has completed and ongoing research activities and gave many talks in his speciality.
Sessions by this speaker
Thursday,
-
08:30 - 11:00
Welcome Note
Dr. Muhammad Faisal Khanani | United Arab Emirates

Dr. Muhammad Faisal Khanani
Chief of Hematology/Oncology PEDS
Chief of Hematology/Oncology PEDS – Tawam Hospital
Sessions by this speaker
Friday, 2022-11-25
Scientific Committee
00:00 - 23:55
Lectures by this speaker
Sunday, 2022-11-27
Welcome Note
08:30 - 08:32
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30
08:30 - 08:32
Medulloblastoma – current treatment and management

Dr. Trent Hummel
Associate Professor of Clinical Pediatrics
Dr. Hummel's clinical and academic interests pertain to children and families affected by central nervous system tumors. He focuses on developing novel therapeutics to treat children with all central nervous system tumors including those patients with neurofibromatosis type 1 and 2 related CNS tumors and very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine glioma.
Lectures by this speaker
Sunday, 2022-11-27
Medulloblastoma – current treatment and management
08:30 - 08:55
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30
08:30 - 08:55
Neuroblastoma treatment and immunotherapy

Dr. Brian Weiss
Professor of Clinical Pediatrics
"Dr. Weiss specializes in caring for children with neuroblastoma and neurofibromatosis type 1 (NF1) related plexiform neurofibromas. He researches novel therapies and targeted radiotherapy to treat neuroblastoma, particularly high-risk neuroblastoma. He is also investigating the development of targeted therapies for NF1 related plexiform neurofibromas. "
Lectures by this speaker
Sunday, 2022-11-27
Neuroblastoma treatment and immunotherapy
08:55 - 09:20
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30
08:55 - 09:20
Non- Hodgkin Lymphoma in paediatric – Classification and current management

Dr. Jeremy Rubinstein
Assistant Professor of Pediatrics
Dr. Rubinstein specializes in treating pediatric leukemia and lymphoma, emphasizing the use of cellular therapy. His research focuses on using new a+O48nd emerging cellular therapy techniques to better treat difficult-to-manage leukemias and lymphomas and the management of important side effects such as viral infections
Lectures by this speaker
Sunday, 2022-11-27
Non- Hodgkin Lymphoma in paediatric – Classification and current management
09:20 - 09:45
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30
09:20 - 09:45
Sarcoma in paediatric current treatment options

Dr. Joseph Pressey
Professor of Clinical Pediatrics
Dr. Pressey joined the Cancer and Blood Diseases Institute at Cincinnati Children's to direct the Sarcoma and Young Adult Oncology Programs in 2014. He is appointed Professor of Clinical Pediatrics at the University of Cincinnati College of Medicine and functions as the Cincinnati Children's Institutional PI for the COG Pediatric Early Phase Clinical Trials Network (PEP-CTN) and SARC, as well as, for many industry-sponsored trials.
Lectures by this speaker
Sunday, 2022-11-27
Sarcoma in paediatric current treatment options
09:45 - 10:10
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30
09:45 - 10:10
Panel Discussion and Q&A’s
Dr. Naser Alzein | United Arab Emirates

Dr. Naser Alzein
Chief Division of pediatric hematology/oncology
Dr Naser is currently serving as Chief Division of pediatric hematology/oncology at Sheikh Khalifa Medical City (SKMC). Dr Naser joined SKMC in 2009. Before that, he served as the medical director of pediatric hematology/oncology at Blank Children’s Hospital in Des Moines, Iowa in the United States of America. He is an assistant professor of pediatrics/pediatric hematology/Oncology at Carver College of Medicine at the University of Iowa in the United States. Dr Naser completed his medical school from Jordan University of Science and Technology in Jordan in 1993, and then he did his PhD in Pediatrics at the University of Jordan. Dr Alzein, completed his training in the United States of America. He is double American board certified in Pediatrics and pediatric Hematology/Oncology. Dr Naser has major interest in Lymphoma and hematological malignancies, as well as benign hematology like hemoglobinopathies He is a 2 times winner of the American Society of Oncology (ASCO) Merit Award; for the best translational medicine research abstract in cancer genetic. In addition, he won the Lymphoma Spore Group Grant Award in 2005 for his work on DNA methylation in B cell Lymphomas. In addition, Dr Alzein won 3 times the Best Teaching Award from the Education Department at SKMC Dr Alzein, has great experience in bone marrow transplant and solid tumors as well. Dr Alzein has been a speaker in several International and regional meetings. He has multiple publications related to his field.
Sessions by this speaker
Sunday, 2022-11-27
Session 1: Paediatric Oncology
08:30 - 11:00
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30

Dr. Jeremy Rubinstein
Assistant Professor of Pediatrics
Dr. Rubinstein specializes in treating pediatric leukemia and lymphoma, emphasizing the use of cellular therapy. His research focuses on using new a+O48nd emerging cellular therapy techniques to better treat difficult-to-manage leukemias and lymphomas and the management of important side effects such as viral infections
Lectures by this speaker
Sunday, 2022-11-27
Non- Hodgkin Lymphoma in paediatric – Classification and current management
09:20 - 09:45
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30

Dr. Brian Weiss
Professor of Clinical Pediatrics
"Dr. Weiss specializes in caring for children with neuroblastoma and neurofibromatosis type 1 (NF1) related plexiform neurofibromas. He researches novel therapies and targeted radiotherapy to treat neuroblastoma, particularly high-risk neuroblastoma. He is also investigating the development of targeted therapies for NF1 related plexiform neurofibromas. "
Lectures by this speaker
Sunday, 2022-11-27
Neuroblastoma treatment and immunotherapy
08:55 - 09:20
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30

Dr. Joseph Pressey
Professor of Clinical Pediatrics
Dr. Pressey joined the Cancer and Blood Diseases Institute at Cincinnati Children's to direct the Sarcoma and Young Adult Oncology Programs in 2014. He is appointed Professor of Clinical Pediatrics at the University of Cincinnati College of Medicine and functions as the Cincinnati Children's Institutional PI for the COG Pediatric Early Phase Clinical Trials Network (PEP-CTN) and SARC, as well as, for many industry-sponsored trials.
Lectures by this speaker
Sunday, 2022-11-27
Sarcoma in paediatric current treatment options
09:45 - 10:10
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30

Dr. Trent Hummel
Associate Professor of Clinical Pediatrics
Dr. Hummel's clinical and academic interests pertain to children and families affected by central nervous system tumors. He focuses on developing novel therapeutics to treat children with all central nervous system tumors including those patients with neurofibromatosis type 1 and 2 related CNS tumors and very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine glioma.
Lectures by this speaker
Sunday, 2022-11-27
Medulloblastoma – current treatment and management
08:30 - 08:55
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30
Dr. Omran El Koha | United Arab Emirates

Dr. Omran El Koha
Consultant Radiation /Clinical Oncologist
Dr. Omran is an experienced clinical oncologist with a demonstrated history of working in the medical and radiation oncology p . Skilled in Clinical Research, Medical Education, Strategic Planning. Strong education professional with a Master's Degree focused in Health research ethics
Sessions by this speaker
Sunday, 2022-11-27
Session 1: Paediatric Oncology
08:30 - 11:00
Saturday, 2022-11-26
Session 7: Lung Cancer Session
15:40 - 17:30
Lectures by this speaker
Saturday, 2022-11-26
Voting + Panel discussion
17:00 - 17:10
Sunday, 2022-11-27
Case Presentation Lung Cancer
14:00 - 14:45
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30
Dr. Mustafa Baroudi | United Arab Emirates

Dr. Mustafa Baroudi
Consultant Pediatric Oncologist Hematologist
Dr Mustafa Baroudi is a Consultant Pediatric Oncologist Hematologist at NMC Royal Khalifa City, Abu Dhabi, UAE.
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30
Dr. Zainul Aabideen | United Arab Emirates

Dr. Zainul Aabideen
Consultant Paediatric
"Dr. Zainul is a highly skilled and experienced in Paediatric Haematology and Oncology. He received his Degree in Medicine at Calicut University in Kerala, India, subsequently he took his Post - Graduate degree in Paediatrics from the University of Mumbai. In 2001, Dr. Zainul moved to the United Kingdom where he specialize and undertake further training and experience in paediatric haematology, paediatric oncology and Paediatric Bone Marrow Transplantation in various hospitals in UK. Dr. Zainul gained his master’s degree in Paediatric Oncology at Birmingham University as well as Certificate in Medical Education at Manchester University. Subsequently, he completed his International Fellowship in Paediatric Bone Marrow Transplantation at Great North Children’s Hospital in Newcastle. He worked previously as Consultant Pediatric at University Hospital of Coventry and Warwickshare and Royal Oldham Hospital before moving to UAE. In the UAE, He had worked at Department of Pediatric hematology and Oncvology Tawam Hospital as Consultant, Al Ain, before he joined at Burjeel Medical City. Aside from his commitment to further advance his experience and knowledge in the field of Paediatrics, Paediatric Haematology, Oncology and Bone Marrow Transplantation in the United Kingdom he also published numerous articles and actively support by sharing his knowledge to the community by participating international conference across countries."
Sessions by this speaker
Sunday, 2022-11-27
Session 1: Paediatric Oncology
08:30 - 11:00
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30
Dr. Muhammad Faisal Khanani | United Arab Emirates

Dr. Muhammad Faisal Khanani
Chief of Hematology/Oncology PEDS
Chief of Hematology/Oncology PEDS – Tawam Hospital
Sessions by this speaker
Friday, 2022-11-25
Scientific Committee
00:00 - 23:55
Lectures by this speaker
Sunday, 2022-11-27
Welcome Note
08:30 - 08:32
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30
10:10 - 10:30
COFFEE BREAK
10:30 - 11:00
Session 3: Gastrointestinal Session
Dr. Diaeddine Trad | United Arab Emirates

Dr. Diaeddine Trad
Consultant Physician, Oncology Clinic | United Arab Emirates
Dr. Diaeddine Trad is a Consultant of Medical Oncology, at Tawam Hospital, in Al Ain, UAE. He is a member of the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). He is an investigator in several ongoing clinical trials. Dr. Trad is certified as a specialist in internal medicine, hematology and oncology by the Lebanese Ministry of Health. His research interests include; non-small cell lung adenocarcinoma and locally advanced breast cancer. Dr. Trad was a speaker in many international conferences and forums.
Sessions by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Lectures by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Chairperson:
Dr. Omar Bekdache | United Arab Emirates

Dr. Omar Bekdache
Consultant General Surgeon | United Arab Emirates
"Omar A. Bekdache, MD, MSc, FRCS, FACS, EBSQ is a Consultant General Surgeon at Tawam Hospital – former Johns Hopkins affiliate, currently holding the position of Chief of Trauma Services and Chairman of Trauma Committee. Dr Bekdache obtained his medical degree from Lebanese University School of Medicine and residency training in General Surgery at the American University of Beirut Medical center and MGH. Dr Bekdache has completed a clinical fellowship in Minimal Invasive surgery from the University of Lille – France. He obtained in addition a University Diploma in Hepato-Biliary Surgery from the University of Paris XI – Paul Brousse Hospital / Villejuif Paris – France and completed the European Board of Surgical Oncology."
Sessions by this speaker
Thursday,
-
Lectures by this speaker
Thursday,
-
Chairperson:
Dr. Hassan Ghazal | United Arab Emirates

Dr. Hassan Ghazal
Consultant Medical Oncologist & Consultant Clinical Hematologist | United Arab Emirates
"Dr Hassan Ghazal is an American board-certified Consultant Medical Oncologist and a Consultant Clinical hematologist offering more than 3 decades of clinical experience. Dr Hassan Ghazal, after doing his basic medical education in American University of Beirut, moved to US for his residency program in Internal Medicine at Sinai Hospital of Baltimore, MD. In 1992, completing the residency program, Dr Hassan Ghazal joined in George Washington university Medical Center for his fellowship in Medical Oncology and completed the same in 1995. He continued in George Washington University Medical Center for another 2 years and obtained his senior fellowship in bone marrow transplantation in the year 1997. He got his US board certification in Internal Medicine, Medical Oncology and in Hematology in the year 1992, 1995,1996 respectively. Except his association with CMC for the preceding 3 years, all his clinical practices were in US in various capacities including Director, Kentucky Cancer Clinic and Staff Oncologist/ Hematologist at Hazard Appalachian Regional Medical Center. Dr Hassan Ghazal is a member of various clinical societies such as American College of Physicians, American Society of Haematology, American Society of Clinical Oncology, European Society of Medical Oncology etc. Dr Hassan Ghazal has got many publications and abstracts in his credit, in peer reviewed journals, and there are many international recognitions and accolades in his name. He has been involved in numerous clinical trials, nearly 100, in the US, serving as Principal Investigator, for over 25 years, and enrolled hundreds of patients in these trials."
Sessions by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Lectures by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Chairperson:
Dr. Abdul Rahman Al Kinge | United Arab Emirates

Dr. Abdul Rahman Al Kinge
Medical Oncologist | United Arab Emirates
Dr. Abdul Rahman Agha El Kinge has an extensive experience in Medical Oncology. He has trained in Breast Cancer at the MD Anderson Cancer Center, USA, and he is also certified by the European Society of Medical Oncology. Dr. El Kinge is on the editorial board and a reviewer in multiple international medical journals. He is a Fellow of the American College of Physicians, and a member of local and international hematology and oncology societies. He has a keen interest in academics and as a result has multiple peer-reviewed publications. He has initiated and headed multiple oncology and hematology departments in KSA and UAE. He is the Chairperson of the yearly International Oncology and Supportive Care Congress. He has special interest and experience in Precision Medicine and Artificial intelligence in Cancer care.
Sessions by this speaker
Thursday,
-
Lectures by this speaker
Thursday,
-
Updates in the Management of First-line Advanced Gastric Cancer
Dr. Husam Marashi | United Kingdom

Dr. Husam Marashi
Consultant Clinical Oncologist
Dr Husam Marashi is a Consultant Clinical Oncologist based at the Beatson West of Scotland Cancer Centre and Rosshall Hospital. He underwent post graduate training at the West of Scotland hospitals and became a consultant in 2015. He developed a special interest in the non-surgical management of Upper gastro-intestinal and Breast malignancies including chemotherapy, radiotherapy, targeted therapy and immunotherapy. He is a principle investigator for many clinical trials and involved in many precision medicine programmes. He is also an active member of the oligometastasis SABR radiotherapy team. Dr Marashi has an active role in medical education/training for clinical oncology trainees in Scotland, and a member of RCR recruitment team. He is a member of the breast cancer MCN advisory board for the West of Scotland.
Lectures by this speaker
Sunday, 2022-11-27
Updates in the Management of First-line Advanced Gastric Cancer
11:00 - 11:20
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
11:00 - 11:20
Management Updates on Advanced HCC
Prof. Daniel Palmer | United Kingdom

Prof. Daniel Palmer
Professor and Honorary Consultant in Medical Oncology
Professor Palmer took his current position of North West Cancer Research Chair in Medical Oncology at the University of Liverpool in 2011. His research interests relate to HPB cancers (liver, pancreas and biliary tract) and incorporate basic laboratory science, translational research and clinical trials. His laboratory research is currently investigating novel therapeutic approaches to the treatment of HPB cancer through stimulation of anti-tumour immune responses and targeting tumour micro-environment including the tumour microbiome, and developing and validating biomarkers for a stratified approach to treatment. He is a member of the UK NCRN Upper GI cancers clinical studies group, and the hepatobiliary and pancreatic sub-groups. He is Director of the Cancer Research UK/NIHR Liverpool Experimental Cancer Medicine Centre and has established a portfolio of early phase clinical trials and translational studies and he is Chief Investigator for the TACE-3 and RaTIO trials investigating immunotherapy combinations for patients with intermediate and advanced HCC respectively.
Lectures by this speaker
Friday, 2022-11-25
Plenary 2: New Insights in to the Cancer-Microbiome-Immune axis
09:00 - 09:20
Friday, 2022-11-25
Panel Discussion
09:40 - 10:00
Sunday, 2022-11-27
Management Updates on Advanced HCC
11:20 - 11:40
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Recent Advances in Management of Cholangiocarcinoma
15:40 - 16:00
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
11:20 - 11:40
Role of ctDNA in Colorectal Cancer Management
Dr. Atif Iqbal | United Arab Emirates

Dr. Atif Iqbal
Associate Professor and Chief, Section of Colorectal Surgery
"Dr. Atif Iqbal earned his medical degree from King Edward Medical University and completed a surgical internship at Mayo Hospital, Pakistan. He then completed a surgical research fellowship at Creighton University Medical Center in Omaha, Nebraska, followed by a general surgery residency at the University of Missouri and a colon and rectal surgery fellowship at Washington University/Barnes-Jewish Hospital in St. Louis. He joined the University of Florida (UF) as an assistant professor in 2011 and was promoted to associate professor in 2018. Dr. Iqbal leads the Colorectal Surgery team, and specializes in surgical procedures for benign and malignant pathology of the colon, rectum and anus. He has a special interest in advanced laparoscopic and robotic surgical procedures for colon and rectal cancer, including sphincter saving procedures for low rectal cancer. He is a member of the Baylor Inflammatory Bowel Disease Center and offers laparoscopic pouch procedures for ulcerative colitis and minimally invasive surgery for Crohn’s disease."
Lectures by this speaker
Sunday, 2022-11-27
Role of ctDNA in Colorectal Cancer Management
11:40 - 12:00
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
11:40 - 12:00
Optimizing the 1st line treatment in mCRC - Supported by Merck

Prof. Dirk Arnold
Director
"Dirk Arnold is Director of the Asklepios Tumorzentrum Hamburg, a network cancer centre serving 7 community hospitals in Hamburg, and also Head of the department of Oncology, Haematology and Palliative Care at AK Altona, Hamburg. Before taking this position, he was 2010 appointed as Director of the University Cancer Centre in Hamburg (UCCH) and held positions at the University Departments for Oncology and Haematology in Halle-Wittenberg, Freiburg and Berlin. Between 2015 and 2017, he served as Director of the Instituto CUF de Oncologia in Lisbon, Portugal. His major field of scientific interest are gastrointestinal cancers, and here specifically modern therapeutic approaches in biomarker-driven decision processes, and multimodal treatment strategies, also including other specialities. Here, he has served as chairman of Colorectal Cancer Study Group of the German AIO, a major collaborative group in clinical oncology. Within the AIO framework, he served as founding member of the Central Clinical Trials Office, underlining his expertise also in methodology of clinical research. Furthermore, his interest is the organisation of larger collaborative research structures and of integrated cancer centre networks. Prof. Arnold is also member of the American Society of Clinical Oncology and Task Force Member of the National Cancer Institute, as well as Board member of the EORTC GI study group."
Lectures by this speaker
Sunday, 2022-11-27
Optimizing the 1st line treatment in mCRC - Supported by Merck
12:00 - 12:20
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Dr. Emad Dawoud | United Arab Emirates

Dr. Emad Dawoud
Consultant Physician, Oncology Clinic
Dr. Emad Dawoud is a Consultant Medical Oncologist in Oncology department at Tawam hospital UAE, and Assistant professor of clinical oncology in Al Azhar University Cairo, Egypt. Dr. Dawoud has been principal investigator and co- investigator for more than 50 clinical trials and abstract published per reviewed journals and he is a member of various associations such as ASCO, ESMO, ESTRO.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Friday, 2022-11-25
Session 3: Gynaecological cancers
11:20 - 14:00
Friday, 2022-11-25
Session 5: Gynaecological Cancers
14:00 - 15:40
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Saturday, 2022-11-26
Session 1: Early Breast Cancer Session
08:30 - 11:00
Lectures by this speaker
Friday, 2022-11-25
Management of endometrial cancer in the molecular era
15:40 - 16:00
Friday, 2022-11-25
Panel Discussion- Q&A
15:00 - 15:20
Friday, 2022-11-25
Endometrial Cancer - Case Based Discussion
12:00 - 12:30
Friday, 2022-11-25
Panel Discussion
12:30 - 12:40
Friday, 2022-11-25
Panel Discussion- Q&A
16:20 - 16:30
Saturday, 2022-11-26
Recent Advances in Systemic Therapy in Resected Lung Cancer - Supported by Roche
14:40 - 15:00
Saturday, 2022-11-26
Panel Discussion and Q&A’s
15:00 - 15:10
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen
10:20 - 10:40
Sunday, 2022-11-27
Case Presentation Lung Cancer
14:00 - 14:45
Sunday, 2022-11-27
Optimizing the 1st line treatment in mCRC - Supported by Merck
12:00 - 12:20
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
Saturday, 2022-11-26
Early Breast Cancer and the Use of Abemacilcib to Prevent Recurrence in Patients with HR+, HER2- with High Risk of Recurrence - Supported by Lilly
09:50 - 10:10
12:00 - 12:20
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly
Dr. Diaeddine Trad | United Arab Emirates

Dr. Diaeddine Trad
Consultant Physician, Oncology Clinic
Dr. Diaeddine Trad is a Consultant of Medical Oncology, at Tawam Hospital, in Al Ain, UAE. He is a member of the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). He is an investigator in several ongoing clinical trials. Dr. Trad is certified as a specialist in internal medicine, hematology and oncology by the Lebanese Ministry of Health. His research interests include; non-small cell lung adenocarcinoma and locally advanced breast cancer. Dr. Trad was a speaker in many international conferences and forums.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Saturday, 2022-11-26
Session 5: Lung Cancer Session
14:00 - 15:40
Sunday, 2022-11-27
Session 3: Gastrointestinal Session
11:00 - 14:00
Saturday, 2022-11-26
Session 7: Lung Cancer Session
15:40 - 17:30
Lectures by this speaker
Saturday, 2022-11-26
Real world effectiveness data for MBC patients – Supported by Pfizer
12:20 - 12:40
Saturday, 2022-11-26
Panel Discussion and Q&A
13:00 - 13:10
Saturday, 2022-11-26
Panel Discussion and Q&A’s
15:00 - 15:10
Saturday, 2022-11-26
Closing Remarks
17:10 - 17:20
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Sunday, 2022-11-27
Meeting Close
16:35 - 16:40
Sunday, 2022-11-27
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly
12:20 - 12:40
Dr. Nouri Bennini | United Arab Emirates

Dr. Nouri Bennini
Consultant Physician, Oncology Clinic
Dr.Nouri Bennini is a Consultant Physician, Oncology Clinic at Tawam Hospital.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Saturday, 2022-11-26
Session 1: Early Breast Cancer Session
08:30 - 11:00
Sunday, 2022-11-27
Session 5: Gastrointestinal Session
14:00 - 16:40
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s
10:10 - 10:30
Saturday, 2022-11-26
Beyond Covid 19 Vaccination : Evusheld (Tixagevimab and Cilgevimab ) for the Prevention and Treatment of Covid 19 among the High Risk Patients - Supported by AstraZeneca
15:10 - 15:30
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Dual Immunotherapy Approach in 1L RCC Treatment - Supported by BMS
11:20 - 11:50
Sunday, 2022-11-27
Case Presentation Breast Cancer
14:45 - 15:30
Sunday, 2022-11-27
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly
12:20 - 12:40
12:20 - 12:40
Panel Discussion and Q & A
Dr. Hassan Ghazal | United Arab Emirates

Dr. Hassan Ghazal
Consultant Medical Oncologist & Consultant Clinical Hematologist
"Dr Hassan Ghazal is an American board-certified Consultant Medical Oncologist and a Consultant Clinical hematologist offering more than 3 decades of clinical experience. Dr Hassan Ghazal, after doing his basic medical education in American University of Beirut, moved to US for his residency program in Internal Medicine at Sinai Hospital of Baltimore, MD. In 1992, completing the residency program, Dr Hassan Ghazal joined in George Washington university Medical Center for his fellowship in Medical Oncology and completed the same in 1995. He continued in George Washington University Medical Center for another 2 years and obtained his senior fellowship in bone marrow transplantation in the year 1997. He got his US board certification in Internal Medicine, Medical Oncology and in Hematology in the year 1992, 1995,1996 respectively. Except his association with CMC for the preceding 3 years, all his clinical practices were in US in various capacities including Director, Kentucky Cancer Clinic and Staff Oncologist/ Hematologist at Hazard Appalachian Regional Medical Center. Dr Hassan Ghazal is a member of various clinical societies such as American College of Physicians, American Society of Haematology, American Society of Clinical Oncology, European Society of Medical Oncology etc. Dr Hassan Ghazal has got many publications and abstracts in his credit, in peer reviewed journals, and there are many international recognitions and accolades in his name. He has been involved in numerous clinical trials, nearly 100, in the US, serving as Principal Investigator, for over 25 years, and enrolled hundreds of patients in these trials."
Sessions by this speaker
Saturday, 2022-11-26
Session 3: Advanced Breast Cancer Session
11:00 - 14:00
Sunday, 2022-11-27
Session 3: Gastrointestinal Session
11:00 - 14:00
Sunday, 2022-11-27
Session 5: Gastrointestinal Session
14:00 - 16:40
Lectures by this speaker
Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC
11:30 - 11:40
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Dr. Omar Bekdache | United Arab Emirates

Dr. Omar Bekdache
Consultant General Surgeon
"Omar A. Bekdache, MD, MSc, FRCS, FACS, EBSQ is a Consultant General Surgeon at Tawam Hospital – former Johns Hopkins affiliate, currently holding the position of Chief of Trauma Services and Chairman of Trauma Committee. Dr Bekdache obtained his medical degree from Lebanese University School of Medicine and residency training in General Surgery at the American University of Beirut Medical center and MGH. Dr Bekdache has completed a clinical fellowship in Minimal Invasive surgery from the University of Lille – France. He obtained in addition a University Diploma in Hepato-Biliary Surgery from the University of Paris XI – Paul Brousse Hospital / Villejuif Paris – France and completed the European Board of Surgical Oncology."
Sessions by this speaker
Sunday, 2022-11-27
Session 3: Gastrointestinal Session
11:00 - 14:00
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Dr. Husam Marashi | United Kingdom

Dr. Husam Marashi
Consultant Clinical Oncologist
Dr Husam Marashi is a Consultant Clinical Oncologist based at the Beatson West of Scotland Cancer Centre and Rosshall Hospital. He underwent post graduate training at the West of Scotland hospitals and became a consultant in 2015. He developed a special interest in the non-surgical management of Upper gastro-intestinal and Breast malignancies including chemotherapy, radiotherapy, targeted therapy and immunotherapy. He is a principle investigator for many clinical trials and involved in many precision medicine programmes. He is also an active member of the oligometastasis SABR radiotherapy team. Dr Marashi has an active role in medical education/training for clinical oncology trainees in Scotland, and a member of RCR recruitment team. He is a member of the breast cancer MCN advisory board for the West of Scotland.
Lectures by this speaker
Sunday, 2022-11-27
Updates in the Management of First-line Advanced Gastric Cancer
11:00 - 11:20
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Prof. Daniel Palmer | United Kingdom

Prof. Daniel Palmer
Professor and Honorary Consultant in Medical Oncology
Professor Palmer took his current position of North West Cancer Research Chair in Medical Oncology at the University of Liverpool in 2011. His research interests relate to HPB cancers (liver, pancreas and biliary tract) and incorporate basic laboratory science, translational research and clinical trials. His laboratory research is currently investigating novel therapeutic approaches to the treatment of HPB cancer through stimulation of anti-tumour immune responses and targeting tumour micro-environment including the tumour microbiome, and developing and validating biomarkers for a stratified approach to treatment. He is a member of the UK NCRN Upper GI cancers clinical studies group, and the hepatobiliary and pancreatic sub-groups. He is Director of the Cancer Research UK/NIHR Liverpool Experimental Cancer Medicine Centre and has established a portfolio of early phase clinical trials and translational studies and he is Chief Investigator for the TACE-3 and RaTIO trials investigating immunotherapy combinations for patients with intermediate and advanced HCC respectively.
Lectures by this speaker
Friday, 2022-11-25
Plenary 2: New Insights in to the Cancer-Microbiome-Immune axis
09:00 - 09:20
Friday, 2022-11-25
Panel Discussion
09:40 - 10:00
Sunday, 2022-11-27
Management Updates on Advanced HCC
11:20 - 11:40
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Recent Advances in Management of Cholangiocarcinoma
15:40 - 16:00
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Dr. Atif Iqbal | United Arab Emirates

Dr. Atif Iqbal
Associate Professor and Chief, Section of Colorectal Surgery
"Dr. Atif Iqbal earned his medical degree from King Edward Medical University and completed a surgical internship at Mayo Hospital, Pakistan. He then completed a surgical research fellowship at Creighton University Medical Center in Omaha, Nebraska, followed by a general surgery residency at the University of Missouri and a colon and rectal surgery fellowship at Washington University/Barnes-Jewish Hospital in St. Louis. He joined the University of Florida (UF) as an assistant professor in 2011 and was promoted to associate professor in 2018. Dr. Iqbal leads the Colorectal Surgery team, and specializes in surgical procedures for benign and malignant pathology of the colon, rectum and anus. He has a special interest in advanced laparoscopic and robotic surgical procedures for colon and rectal cancer, including sphincter saving procedures for low rectal cancer. He is a member of the Baylor Inflammatory Bowel Disease Center and offers laparoscopic pouch procedures for ulcerative colitis and minimally invasive surgery for Crohn’s disease."
Lectures by this speaker
Sunday, 2022-11-27
Role of ctDNA in Colorectal Cancer Management
11:40 - 12:00
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00

Prof. Dirk Arnold
Director
"Dirk Arnold is Director of the Asklepios Tumorzentrum Hamburg, a network cancer centre serving 7 community hospitals in Hamburg, and also Head of the department of Oncology, Haematology and Palliative Care at AK Altona, Hamburg. Before taking this position, he was 2010 appointed as Director of the University Cancer Centre in Hamburg (UCCH) and held positions at the University Departments for Oncology and Haematology in Halle-Wittenberg, Freiburg and Berlin. Between 2015 and 2017, he served as Director of the Instituto CUF de Oncologia in Lisbon, Portugal. His major field of scientific interest are gastrointestinal cancers, and here specifically modern therapeutic approaches in biomarker-driven decision processes, and multimodal treatment strategies, also including other specialities. Here, he has served as chairman of Colorectal Cancer Study Group of the German AIO, a major collaborative group in clinical oncology. Within the AIO framework, he served as founding member of the Central Clinical Trials Office, underlining his expertise also in methodology of clinical research. Furthermore, his interest is the organisation of larger collaborative research structures and of integrated cancer centre networks. Prof. Arnold is also member of the American Society of Clinical Oncology and Task Force Member of the National Cancer Institute, as well as Board member of the EORTC GI study group."
Lectures by this speaker
Sunday, 2022-11-27
Optimizing the 1st line treatment in mCRC - Supported by Merck
12:00 - 12:20
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Dr. Abdul Rahman Al Kinge | United Arab Emirates

Dr. Abdul Rahman Al Kinge
Medical Oncologist
Dr. Abdul Rahman Agha El Kinge has an extensive experience in Medical Oncology. He has trained in Breast Cancer at the MD Anderson Cancer Center, USA, and he is also certified by the European Society of Medical Oncology. Dr. El Kinge is on the editorial board and a reviewer in multiple international medical journals. He is a Fellow of the American College of Physicians, and a member of local and international hematology and oncology societies. He has a keen interest in academics and as a result has multiple peer-reviewed publications. He has initiated and headed multiple oncology and hematology departments in KSA and UAE. He is the Chairperson of the yearly International Oncology and Supportive Care Congress. He has special interest and experience in Precision Medicine and Artificial intelligence in Cancer care.
Sessions by this speaker
Sunday, 2022-11-27
Session 3: Gastrointestinal Session
11:00 - 14:00
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Dr. Diaeddine Trad | United Arab Emirates

Dr. Diaeddine Trad
Consultant Physician, Oncology Clinic
Dr. Diaeddine Trad is a Consultant of Medical Oncology, at Tawam Hospital, in Al Ain, UAE. He is a member of the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). He is an investigator in several ongoing clinical trials. Dr. Trad is certified as a specialist in internal medicine, hematology and oncology by the Lebanese Ministry of Health. His research interests include; non-small cell lung adenocarcinoma and locally advanced breast cancer. Dr. Trad was a speaker in many international conferences and forums.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Saturday, 2022-11-26
Session 5: Lung Cancer Session
14:00 - 15:40
Sunday, 2022-11-27
Session 3: Gastrointestinal Session
11:00 - 14:00
Saturday, 2022-11-26
Session 7: Lung Cancer Session
15:40 - 17:30
Lectures by this speaker
Saturday, 2022-11-26
Real world effectiveness data for MBC patients – Supported by Pfizer
12:20 - 12:40
Saturday, 2022-11-26
Panel Discussion and Q&A
13:00 - 13:10
Saturday, 2022-11-26
Panel Discussion and Q&A’s
15:00 - 15:10
Saturday, 2022-11-26
Closing Remarks
17:10 - 17:20
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Sunday, 2022-11-27
Meeting Close
16:35 - 16:40
Sunday, 2022-11-27
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly
12:20 - 12:40
Dr. Emad Dawoud | United Arab Emirates

Dr. Emad Dawoud
Consultant Physician, Oncology Clinic
Dr. Emad Dawoud is a Consultant Medical Oncologist in Oncology department at Tawam hospital UAE, and Assistant professor of clinical oncology in Al Azhar University Cairo, Egypt. Dr. Dawoud has been principal investigator and co- investigator for more than 50 clinical trials and abstract published per reviewed journals and he is a member of various associations such as ASCO, ESMO, ESTRO.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Friday, 2022-11-25
Session 3: Gynaecological cancers
11:20 - 14:00
Friday, 2022-11-25
Session 5: Gynaecological Cancers
14:00 - 15:40
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Saturday, 2022-11-26
Session 1: Early Breast Cancer Session
08:30 - 11:00
Lectures by this speaker
Friday, 2022-11-25
Management of endometrial cancer in the molecular era
15:40 - 16:00
Friday, 2022-11-25
Panel Discussion- Q&A
15:00 - 15:20
Friday, 2022-11-25
Endometrial Cancer - Case Based Discussion
12:00 - 12:30
Friday, 2022-11-25
Panel Discussion
12:30 - 12:40
Friday, 2022-11-25
Panel Discussion- Q&A
16:20 - 16:30
Saturday, 2022-11-26
Recent Advances in Systemic Therapy in Resected Lung Cancer - Supported by Roche
14:40 - 15:00
Saturday, 2022-11-26
Panel Discussion and Q&A’s
15:00 - 15:10
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen
10:20 - 10:40
Sunday, 2022-11-27
Case Presentation Lung Cancer
14:00 - 14:45
Sunday, 2022-11-27
Optimizing the 1st line treatment in mCRC - Supported by Merck
12:00 - 12:20
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
Saturday, 2022-11-26
Early Breast Cancer and the Use of Abemacilcib to Prevent Recurrence in Patients with HR+, HER2- with High Risk of Recurrence - Supported by Lilly
09:50 - 10:10
12:40 - 13:00
Lunch Break
13:00 - 14:00
Session 5: Gastrointestinal Session
Dr. Nouri Bennini | United Arab Emirates

Dr. Nouri Bennini
Consultant Physician, Oncology Clinic | United Arab Emirates
Dr.Nouri Bennini is a Consultant Physician, Oncology Clinic at Tawam Hospital.
Sessions by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Lectures by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Chairperson:
Dr. Hassan Ghazal | United Arab Emirates

Dr. Hassan Ghazal
Consultant Medical Oncologist & Consultant Clinical Hematologist | United Arab Emirates
"Dr Hassan Ghazal is an American board-certified Consultant Medical Oncologist and a Consultant Clinical hematologist offering more than 3 decades of clinical experience. Dr Hassan Ghazal, after doing his basic medical education in American University of Beirut, moved to US for his residency program in Internal Medicine at Sinai Hospital of Baltimore, MD. In 1992, completing the residency program, Dr Hassan Ghazal joined in George Washington university Medical Center for his fellowship in Medical Oncology and completed the same in 1995. He continued in George Washington University Medical Center for another 2 years and obtained his senior fellowship in bone marrow transplantation in the year 1997. He got his US board certification in Internal Medicine, Medical Oncology and in Hematology in the year 1992, 1995,1996 respectively. Except his association with CMC for the preceding 3 years, all his clinical practices were in US in various capacities including Director, Kentucky Cancer Clinic and Staff Oncologist/ Hematologist at Hazard Appalachian Regional Medical Center. Dr Hassan Ghazal is a member of various clinical societies such as American College of Physicians, American Society of Haematology, American Society of Clinical Oncology, European Society of Medical Oncology etc. Dr Hassan Ghazal has got many publications and abstracts in his credit, in peer reviewed journals, and there are many international recognitions and accolades in his name. He has been involved in numerous clinical trials, nearly 100, in the US, serving as Principal Investigator, for over 25 years, and enrolled hundreds of patients in these trials."
Sessions by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Lectures by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Chairperson:
Dr. Sadir Alrawi | United Arab Emirates

Dr. Sadir Alrawi
Consultant Surgical Oncology | United Arab Emirates
Dr. Alrawi is currently the Director of Oncology Services at Burjeel Holdings in the UAE and MENA. He oversees tertiary referral cancer centers for the entire UAE and palliative care and research. Dr. Alrawi was the Director of Oncology Services (Surgery and Oncology) at Alzahra Hospital in the heart of Dubai and the hospital’s tertiary referral cancer center for the entire UAE, where he oversaw highly specialized surgical oncology subspecialties such as colorectal, breast, head and neck, urology, gynecological, sarcoma/melanoma, and peritoneal surface mal From October 2013 to September 2015, Dr. Alrawi served as Chief of the Surgical Oncology Division at Tawam Hospital and Interim Chair of the Department of Surgery. John Hopkins Medical System is affiliated with Tawam Hospital. Dr. Alrawi’s primary area of interest is gastrointestinal oncology, which encompasses esophageal, gastric, pancreas, liver, colonic surgery, and endocrine surgery, including thyroid, parathyroid, and adrenal surgery. Dr. Alrawi received his surgical oncology training at various academic institutions throughout the country, including Roswell Park Cancer Institute in Buffalo, the Royal Free Hospital at the University of London, and Ninewells Hospital at the University of Dundee. Dr. Alrawi is an American Board-Certified physician who completed his Head and Neck Surgery and Surgical Oncology Fellowships at Roswell Park Cancer Institute (NCI) in 2006. Dr. Alrawi trained in advanced laparoscopic oncology from 1992 to 1993 with Professor Alfred Cuschieri in Dundee, advanced colorectal oncology from 1993 to 1995 with E Lloyd Davis in Cornwall, England, and advanced surgical oncology from 1995 to 1996 with Professor Marc Winslett in London. He has received numerous academic honors during his training and clinical practice years. He is a frequently invited speaker at public and professional meetings devoted to cancer management education. Throughout his career, Dr. Alrawi has been involved in various research activities to increase our understanding of cancer early detection and multidisciplinary approaches. Dr. Alrawi has published over 50 papers in peer-reviewed journals and over 150 presentations at local, national, and international meetings in clinical and basic sciences throughout his 30-year career in surgical oncology. He has also authored ten book chapters. Dr. Alrawi is committed to community outreach and firmly believes that cancer care and health awareness, combined with excellence in cancer diagnosis and treatment delivered by a multidisciplinary team, can and will save lives.
Sessions by this speaker
Thursday,
-
Lectures by this speaker
Thursday,
-
MRI in Rectal Cancer - What the Oncologist and Surgeon wants and How it makes the difference?
Dr. Dinesh Chinchure | Singapore

Dr. Dinesh Chinchure
Senior Consultant in Department of Diagnostic Radiology
Dr. Dinesh Chinchure is a Senior Consultant in Department of Diagnostic Radiology, Khoo Teck Puat Hospital, Singapore. He is also Training Advisor, Quality Lead and Clinical Advisor (IT and PACS) in the department. Concurrently he holds the teaching posts of Clinical Senior Lecturer at YLL National University of Singapore (NUS) School of Medicine and Adjunct Senior Lecturer, LKC School of Medicine, NTU Singapore. He is also a Core Faculty in NHG Diagnostic Radiology Residency Programme. Dr. Dinesh is a member of the editorial board of journal Emergency Radiology, published by American Society of Emergency Radiology (ASER). He is a reviewer for several journals including Clinical Radiology.
Lectures by this speaker
Sunday, 2022-11-27
MRI in Rectal Cancer - What the Oncologist and Surgeon wants and How it makes the difference?
14:00 - 14:20
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
14:00 - 14:20
Non-Surgical Options for Localised Rectal Cancer Management
Prof. Marwan Ghosn | United Arab Emirates

Prof. Marwan Ghosn
Professor and Chairman Hematology Oncology Department
"Professor Marwan Ghosn acquired his medical degree and his post-graduate expertise in Hematology Oncology from Faculty of Medicine, Saint Joseph University in Beirut- Lebanon; as well as from the University of Paris XI, Le Kremlin Bicêtre and Institut Gustave Roussy Cancer Center in Villejuif- France. He is the Director of the Hematology Oncology Post-Graduate Program and the Chairman of the Hematology Oncology Department at Faculty of Medicine, Saint Joseph University in Beirut- Lebanon. He acquired a Master in Hospital and Health Management from The Higher School of Business, ESA in Beirut and a Master in the Quality Management of Units for Care Production (MUPS) from the University of Paris VII, Denis Diderot in France. He is currently the Director of the Cancer Center and the Head of Hematology Oncology Division at Clemenceau Medical Center affiliated with Johns Hopkins International in Beirut- Lebanon, and Consultant Medical Oncology at Clemenceau Medical Center in Dubai- United Arab Emirates."
Lectures by this speaker
Sunday, 2022-11-27
Non-Surgical Options for Localised Rectal Cancer Management
14:20 - 14:40
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
14:20 - 14:40
Latest Advances in Surgical Techniques for Colorectal Cancer
Dr. Guido Hein Huib Mannaerts | United Arab Emirates

Dr. Guido Hein Huib Mannaerts
Chair of Surgery Department
Dr Mannaerts, a double Dutch board certified Gastro-intestinal as well as Oncology surgeon, is the Chair of Surgery Department in Tawam Hospital (UAE). He is the director of the high volume bariatric center in Tawam Hospital, which has with 750 cases in 2017 done the highest annual number of cases in the Gulf region. Besides that he is the lead of the surgical oncology unit in Tawam Hospital. He is known from the international fast-track bariatric courses in Rotterdam, The Netherlands, and is the lead investigator in multiple large randomised controlled trials, leading to over 70 Pubmed registered publications. He has performed a PhD on the multimodal treatment of locally advanced rectal and locally recurrent rectal cancer (ISBN 90-367-1418-4).
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Lectures by this speaker
Sunday, 2022-11-27
Latest Advances in Surgical Techniques for Colorectal Cancer
14:40 - 15:00
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
14:40 - 15:00
Colorectal Liver Metastases Resectable vs Unresectable in the Current Era
Dr. Rehan Saif | United Arab Emirates

Dr. Rehan Saif
Consultant General Surgery
Dr. Rehan Saif is an experienced Consultant General & Hepato-Pancreato-Biliary/Abdominal Multi-Organ Transplant Surgeon (Liver/Pancreas/Kidney) at Burjeel Medical City, Abu Dhabi. He completed his MBBS and MS (General Surgery) from JJM Medical College, India. His interest in the field of HPB/GI Surgery and Abdominal Multi-Organ Transplantation led him to the United Kingdom where he spent a total of 13 years gaining further Specialist Higher Surgical Training with a National Training Number leading on to CCT (UK). He is a UK and European Board certified HPB and Abdominal Multi-Organ Transplant Surgeon. He has also completed numerous fellowships in Minimally Invasive Robotic HPB/GI Surgery and Complex Liver Surgery and Transplantation.
Lectures by this speaker
Sunday, 2022-11-27
Colorectal Liver Metastases Resectable vs Unresectable in the Current Era
15:00 - 15:20
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
15:00 - 15:20
Panel Discussion and Q&A’s
Dr. Fahad Ibnshamsah | Saudi Arabia

Dr. Fahad Ibnshamsah
Chairman of Adult Medical Oncology department
Dr Fahad Ibnshamsah is a consultant in Medical Oncology. He is the Chairman of the Adult Medical Oncology Department, Oncology Centre, King Fahad Specialist Hospital in Damam. He is also the Director of Outreach Program in King Fahad Specialist Hospital and Assistant Professor of Internal Medicine at Imam Abdulrahman Bin Faisal University.
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Dr. Hassan Ghazal | United Arab Emirates

Dr. Hassan Ghazal
Consultant Medical Oncologist & Consultant Clinical Hematologist
"Dr Hassan Ghazal is an American board-certified Consultant Medical Oncologist and a Consultant Clinical hematologist offering more than 3 decades of clinical experience. Dr Hassan Ghazal, after doing his basic medical education in American University of Beirut, moved to US for his residency program in Internal Medicine at Sinai Hospital of Baltimore, MD. In 1992, completing the residency program, Dr Hassan Ghazal joined in George Washington university Medical Center for his fellowship in Medical Oncology and completed the same in 1995. He continued in George Washington University Medical Center for another 2 years and obtained his senior fellowship in bone marrow transplantation in the year 1997. He got his US board certification in Internal Medicine, Medical Oncology and in Hematology in the year 1992, 1995,1996 respectively. Except his association with CMC for the preceding 3 years, all his clinical practices were in US in various capacities including Director, Kentucky Cancer Clinic and Staff Oncologist/ Hematologist at Hazard Appalachian Regional Medical Center. Dr Hassan Ghazal is a member of various clinical societies such as American College of Physicians, American Society of Haematology, American Society of Clinical Oncology, European Society of Medical Oncology etc. Dr Hassan Ghazal has got many publications and abstracts in his credit, in peer reviewed journals, and there are many international recognitions and accolades in his name. He has been involved in numerous clinical trials, nearly 100, in the US, serving as Principal Investigator, for over 25 years, and enrolled hundreds of patients in these trials."
Sessions by this speaker
Saturday, 2022-11-26
Session 3: Advanced Breast Cancer Session
11:00 - 14:00
Sunday, 2022-11-27
Session 3: Gastrointestinal Session
11:00 - 14:00
Sunday, 2022-11-27
Session 5: Gastrointestinal Session
14:00 - 16:40
Lectures by this speaker
Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC
11:30 - 11:40
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Dr. Dinesh Chinchure | Singapore

Dr. Dinesh Chinchure
Senior Consultant in Department of Diagnostic Radiology
Dr. Dinesh Chinchure is a Senior Consultant in Department of Diagnostic Radiology, Khoo Teck Puat Hospital, Singapore. He is also Training Advisor, Quality Lead and Clinical Advisor (IT and PACS) in the department. Concurrently he holds the teaching posts of Clinical Senior Lecturer at YLL National University of Singapore (NUS) School of Medicine and Adjunct Senior Lecturer, LKC School of Medicine, NTU Singapore. He is also a Core Faculty in NHG Diagnostic Radiology Residency Programme. Dr. Dinesh is a member of the editorial board of journal Emergency Radiology, published by American Society of Emergency Radiology (ASER). He is a reviewer for several journals including Clinical Radiology.
Lectures by this speaker
Sunday, 2022-11-27
MRI in Rectal Cancer - What the Oncologist and Surgeon wants and How it makes the difference?
14:00 - 14:20
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Prof. Marwan Ghosn | United Arab Emirates

Prof. Marwan Ghosn
Professor and Chairman Hematology Oncology Department
"Professor Marwan Ghosn acquired his medical degree and his post-graduate expertise in Hematology Oncology from Faculty of Medicine, Saint Joseph University in Beirut- Lebanon; as well as from the University of Paris XI, Le Kremlin Bicêtre and Institut Gustave Roussy Cancer Center in Villejuif- France. He is the Director of the Hematology Oncology Post-Graduate Program and the Chairman of the Hematology Oncology Department at Faculty of Medicine, Saint Joseph University in Beirut- Lebanon. He acquired a Master in Hospital and Health Management from The Higher School of Business, ESA in Beirut and a Master in the Quality Management of Units for Care Production (MUPS) from the University of Paris VII, Denis Diderot in France. He is currently the Director of the Cancer Center and the Head of Hematology Oncology Division at Clemenceau Medical Center affiliated with Johns Hopkins International in Beirut- Lebanon, and Consultant Medical Oncology at Clemenceau Medical Center in Dubai- United Arab Emirates."
Lectures by this speaker
Sunday, 2022-11-27
Non-Surgical Options for Localised Rectal Cancer Management
14:20 - 14:40
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Dr. Rehan Saif | United Arab Emirates

Dr. Rehan Saif
Consultant General Surgery
Dr. Rehan Saif is an experienced Consultant General & Hepato-Pancreato-Biliary/Abdominal Multi-Organ Transplant Surgeon (Liver/Pancreas/Kidney) at Burjeel Medical City, Abu Dhabi. He completed his MBBS and MS (General Surgery) from JJM Medical College, India. His interest in the field of HPB/GI Surgery and Abdominal Multi-Organ Transplantation led him to the United Kingdom where he spent a total of 13 years gaining further Specialist Higher Surgical Training with a National Training Number leading on to CCT (UK). He is a UK and European Board certified HPB and Abdominal Multi-Organ Transplant Surgeon. He has also completed numerous fellowships in Minimally Invasive Robotic HPB/GI Surgery and Complex Liver Surgery and Transplantation.
Lectures by this speaker
Sunday, 2022-11-27
Colorectal Liver Metastases Resectable vs Unresectable in the Current Era
15:00 - 15:20
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Dr. Sadir Alrawi | United Arab Emirates

Dr. Sadir Alrawi
Consultant Surgical Oncology
Dr. Alrawi is currently the Director of Oncology Services at Burjeel Holdings in the UAE and MENA. He oversees tertiary referral cancer centers for the entire UAE and palliative care and research. Dr. Alrawi was the Director of Oncology Services (Surgery and Oncology) at Alzahra Hospital in the heart of Dubai and the hospital’s tertiary referral cancer center for the entire UAE, where he oversaw highly specialized surgical oncology subspecialties such as colorectal, breast, head and neck, urology, gynecological, sarcoma/melanoma, and peritoneal surface mal From October 2013 to September 2015, Dr. Alrawi served as Chief of the Surgical Oncology Division at Tawam Hospital and Interim Chair of the Department of Surgery. John Hopkins Medical System is affiliated with Tawam Hospital. Dr. Alrawi’s primary area of interest is gastrointestinal oncology, which encompasses esophageal, gastric, pancreas, liver, colonic surgery, and endocrine surgery, including thyroid, parathyroid, and adrenal surgery. Dr. Alrawi received his surgical oncology training at various academic institutions throughout the country, including Roswell Park Cancer Institute in Buffalo, the Royal Free Hospital at the University of London, and Ninewells Hospital at the University of Dundee. Dr. Alrawi is an American Board-Certified physician who completed his Head and Neck Surgery and Surgical Oncology Fellowships at Roswell Park Cancer Institute (NCI) in 2006. Dr. Alrawi trained in advanced laparoscopic oncology from 1992 to 1993 with Professor Alfred Cuschieri in Dundee, advanced colorectal oncology from 1993 to 1995 with E Lloyd Davis in Cornwall, England, and advanced surgical oncology from 1995 to 1996 with Professor Marc Winslett in London. He has received numerous academic honors during his training and clinical practice years. He is a frequently invited speaker at public and professional meetings devoted to cancer management education. Throughout his career, Dr. Alrawi has been involved in various research activities to increase our understanding of cancer early detection and multidisciplinary approaches. Dr. Alrawi has published over 50 papers in peer-reviewed journals and over 150 presentations at local, national, and international meetings in clinical and basic sciences throughout his 30-year career in surgical oncology. He has also authored ten book chapters. Dr. Alrawi is committed to community outreach and firmly believes that cancer care and health awareness, combined with excellence in cancer diagnosis and treatment delivered by a multidisciplinary team, can and will save lives.
Sessions by this speaker
Sunday, 2022-11-27
Session 5: Gastrointestinal Session
14:00 - 16:40
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Dr. Guido Hein Huib Mannaerts | United Arab Emirates

Dr. Guido Hein Huib Mannaerts
Chair of Surgery Department
Dr Mannaerts, a double Dutch board certified Gastro-intestinal as well as Oncology surgeon, is the Chair of Surgery Department in Tawam Hospital (UAE). He is the director of the high volume bariatric center in Tawam Hospital, which has with 750 cases in 2017 done the highest annual number of cases in the Gulf region. Besides that he is the lead of the surgical oncology unit in Tawam Hospital. He is known from the international fast-track bariatric courses in Rotterdam, The Netherlands, and is the lead investigator in multiple large randomised controlled trials, leading to over 70 Pubmed registered publications. He has performed a PhD on the multimodal treatment of locally advanced rectal and locally recurrent rectal cancer (ISBN 90-367-1418-4).
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Lectures by this speaker
Sunday, 2022-11-27
Latest Advances in Surgical Techniques for Colorectal Cancer
14:40 - 15:00
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Dr. Nouri Bennini | United Arab Emirates

Dr. Nouri Bennini
Consultant Physician, Oncology Clinic
Dr.Nouri Bennini is a Consultant Physician, Oncology Clinic at Tawam Hospital.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Saturday, 2022-11-26
Session 1: Early Breast Cancer Session
08:30 - 11:00
Sunday, 2022-11-27
Session 5: Gastrointestinal Session
14:00 - 16:40
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s
10:10 - 10:30
Saturday, 2022-11-26
Beyond Covid 19 Vaccination : Evusheld (Tixagevimab and Cilgevimab ) for the Prevention and Treatment of Covid 19 among the High Risk Patients - Supported by AstraZeneca
15:10 - 15:30
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Dual Immunotherapy Approach in 1L RCC Treatment - Supported by BMS
11:20 - 11:50
Sunday, 2022-11-27
Case Presentation Breast Cancer
14:45 - 15:30
Sunday, 2022-11-27
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly
12:20 - 12:40
15:20 - 15:30
Coffee Break
15:30 - 15:40
Recent Advances in Management of Cholangiocarcinoma
Prof. Daniel Palmer | United Kingdom

Prof. Daniel Palmer
Professor and Honorary Consultant in Medical Oncology
Professor Palmer took his current position of North West Cancer Research Chair in Medical Oncology at the University of Liverpool in 2011. His research interests relate to HPB cancers (liver, pancreas and biliary tract) and incorporate basic laboratory science, translational research and clinical trials. His laboratory research is currently investigating novel therapeutic approaches to the treatment of HPB cancer through stimulation of anti-tumour immune responses and targeting tumour micro-environment including the tumour microbiome, and developing and validating biomarkers for a stratified approach to treatment. He is a member of the UK NCRN Upper GI cancers clinical studies group, and the hepatobiliary and pancreatic sub-groups. He is Director of the Cancer Research UK/NIHR Liverpool Experimental Cancer Medicine Centre and has established a portfolio of early phase clinical trials and translational studies and he is Chief Investigator for the TACE-3 and RaTIO trials investigating immunotherapy combinations for patients with intermediate and advanced HCC respectively.
Lectures by this speaker
Friday, 2022-11-25
Plenary 2: New Insights in to the Cancer-Microbiome-Immune axis
09:00 - 09:20
Friday, 2022-11-25
Panel Discussion
09:40 - 10:00
Sunday, 2022-11-27
Management Updates on Advanced HCC
11:20 - 11:40
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Recent Advances in Management of Cholangiocarcinoma
15:40 - 16:00
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
15:40 - 16:00
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
Dr. Fahad Ibnshamsah | Saudi Arabia

Dr. Fahad Ibnshamsah
Chairman of Adult Medical Oncology department
Dr Fahad Ibnshamsah is a consultant in Medical Oncology. He is the Chairman of the Adult Medical Oncology Department, Oncology Centre, King Fahad Specialist Hospital in Damam. He is also the Director of Outreach Program in King Fahad Specialist Hospital and Assistant Professor of Internal Medicine at Imam Abdulrahman Bin Faisal University.
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Dr. Jamal Alkoteesh | United Arab Emirates

Dr. Jamal Alkoteesh
Consultant and chief of Interventional Radiology
"Dr Jamal ALkoteesh is one of the founder of Interventional Radiology speciality in UAE and he is the longest served (15 YEARS) Interventional Radiologist in SEHA/Abu Dhabi Emirates .He was the first DOH licensed Interventional Radiologists in Abu Dhabi Emirates. Dr. ALkoteesh started working in SEHA as the chief of Interventional Radiology at Sheikh Khalifa Medical city between 2007-2010 where he also managed and established the first Radiology Residency Program in Abu Dhabi Emirate and become the first Radiology residency program director in 2009 when took the challenge to train UAE junior doctors to become the Radiologists of the future. "
Lectures by this speaker
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Dr. Syed Mansoor Hasnain | United Arab Emirates

Dr. Syed Mansoor Hasnain
Consultant Radiation Oncologist
"Dr. Syed Mansoor Hasnain is working in Tawam Hospital, Alain, UAE as Consultant Radiation Oncologist. He joined Tawam Hospital in 2009. He initially trained as surgeon and did fellowship in surgery ,FRCS(Glasg) from Royal College Of Physicians and Surgeons Of Glasgow in 2000. In 2001 he started his career and specialist registrar Training in radiation Oncology under supervision of Faculty of Radiology, The Royal College Of Surgeons In Ireland in Saint Luke’s Hospital. He passed FRCR part 1 from Royal College of Radiologists, London U.K. He did fellowship in radiotherapy ‘FFR RCSI’ from Faculty of Radiology , Royal College Of Surgeons In Ireland in 2007. In 2010 he got CCST 'completion of certified specialist training certificate’ from Faculty of Radiology, The Royal College Of Surgeons In Ireland and entry in to specialist register in Medical Council of Ireland. In Tawam in early 2011, Dr. Mansoor successfully led the commissioning and clinical use of the HiArt TomoTherapy system with IMRT & IGRT, one and only in UAE. . In 2013 Dr. Mansoor chaired RapidArc committee, making sure smooth and swift implementation of RapidArc technology with IMRT & IGRT capability in Tawam. In 2015 Dr. Mansoor was appointed as Adjunct Assistant Professor in College of Medicine and health Sciences in UAE University. . In 2018 as lead radiation oncologist, he successfully led the QUATRO certification of the radiotherapy department by IAEA. He is clinical lead Radiation oncologist for Lymphoma, Sarcoma, Urology & GI tumours. "
Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s
10:30 - 10:40
Saturday, 2022-11-26
CNS Lymphoma debate There is a role of radiotherapy in primary CNS Lymphoma
08:50 - 09:10
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Sunday, 2022-11-27
Case Presentation Breast Cancer
14:45 - 15:30
Dr. Dinesh Chinchure | Singapore

Dr. Dinesh Chinchure
Senior Consultant in Department of Diagnostic Radiology
Dr. Dinesh Chinchure is a Senior Consultant in Department of Diagnostic Radiology, Khoo Teck Puat Hospital, Singapore. He is also Training Advisor, Quality Lead and Clinical Advisor (IT and PACS) in the department. Concurrently he holds the teaching posts of Clinical Senior Lecturer at YLL National University of Singapore (NUS) School of Medicine and Adjunct Senior Lecturer, LKC School of Medicine, NTU Singapore. He is also a Core Faculty in NHG Diagnostic Radiology Residency Programme. Dr. Dinesh is a member of the editorial board of journal Emergency Radiology, published by American Society of Emergency Radiology (ASER). He is a reviewer for several journals including Clinical Radiology.
Lectures by this speaker
Sunday, 2022-11-27
MRI in Rectal Cancer - What the Oncologist and Surgeon wants and How it makes the difference?
14:00 - 14:20
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Prof. Marwan Ghosn | United Arab Emirates

Prof. Marwan Ghosn
Professor and Chairman Hematology Oncology Department
"Professor Marwan Ghosn acquired his medical degree and his post-graduate expertise in Hematology Oncology from Faculty of Medicine, Saint Joseph University in Beirut- Lebanon; as well as from the University of Paris XI, Le Kremlin Bicêtre and Institut Gustave Roussy Cancer Center in Villejuif- France. He is the Director of the Hematology Oncology Post-Graduate Program and the Chairman of the Hematology Oncology Department at Faculty of Medicine, Saint Joseph University in Beirut- Lebanon. He acquired a Master in Hospital and Health Management from The Higher School of Business, ESA in Beirut and a Master in the Quality Management of Units for Care Production (MUPS) from the University of Paris VII, Denis Diderot in France. He is currently the Director of the Cancer Center and the Head of Hematology Oncology Division at Clemenceau Medical Center affiliated with Johns Hopkins International in Beirut- Lebanon, and Consultant Medical Oncology at Clemenceau Medical Center in Dubai- United Arab Emirates."
Lectures by this speaker
Sunday, 2022-11-27
Non-Surgical Options for Localised Rectal Cancer Management
14:20 - 14:40
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Dr. Rehan Saif | United Arab Emirates

Dr. Rehan Saif
Consultant General Surgery
Dr. Rehan Saif is an experienced Consultant General & Hepato-Pancreato-Biliary/Abdominal Multi-Organ Transplant Surgeon (Liver/Pancreas/Kidney) at Burjeel Medical City, Abu Dhabi. He completed his MBBS and MS (General Surgery) from JJM Medical College, India. His interest in the field of HPB/GI Surgery and Abdominal Multi-Organ Transplantation led him to the United Kingdom where he spent a total of 13 years gaining further Specialist Higher Surgical Training with a National Training Number leading on to CCT (UK). He is a UK and European Board certified HPB and Abdominal Multi-Organ Transplant Surgeon. He has also completed numerous fellowships in Minimally Invasive Robotic HPB/GI Surgery and Complex Liver Surgery and Transplantation.
Lectures by this speaker
Sunday, 2022-11-27
Colorectal Liver Metastases Resectable vs Unresectable in the Current Era
15:00 - 15:20
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Prof. Daniel Palmer | United Kingdom

Prof. Daniel Palmer
Professor and Honorary Consultant in Medical Oncology
Professor Palmer took his current position of North West Cancer Research Chair in Medical Oncology at the University of Liverpool in 2011. His research interests relate to HPB cancers (liver, pancreas and biliary tract) and incorporate basic laboratory science, translational research and clinical trials. His laboratory research is currently investigating novel therapeutic approaches to the treatment of HPB cancer through stimulation of anti-tumour immune responses and targeting tumour micro-environment including the tumour microbiome, and developing and validating biomarkers for a stratified approach to treatment. He is a member of the UK NCRN Upper GI cancers clinical studies group, and the hepatobiliary and pancreatic sub-groups. He is Director of the Cancer Research UK/NIHR Liverpool Experimental Cancer Medicine Centre and has established a portfolio of early phase clinical trials and translational studies and he is Chief Investigator for the TACE-3 and RaTIO trials investigating immunotherapy combinations for patients with intermediate and advanced HCC respectively.
Lectures by this speaker
Friday, 2022-11-25
Plenary 2: New Insights in to the Cancer-Microbiome-Immune axis
09:00 - 09:20
Friday, 2022-11-25
Panel Discussion
09:40 - 10:00
Sunday, 2022-11-27
Management Updates on Advanced HCC
11:20 - 11:40
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Recent Advances in Management of Cholangiocarcinoma
15:40 - 16:00
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Dr. Guido Hein Huib Mannaerts | United Arab Emirates

Dr. Guido Hein Huib Mannaerts
Chair of Surgery Department
Dr Mannaerts, a double Dutch board certified Gastro-intestinal as well as Oncology surgeon, is the Chair of Surgery Department in Tawam Hospital (UAE). He is the director of the high volume bariatric center in Tawam Hospital, which has with 750 cases in 2017 done the highest annual number of cases in the Gulf region. Besides that he is the lead of the surgical oncology unit in Tawam Hospital. He is known from the international fast-track bariatric courses in Rotterdam, The Netherlands, and is the lead investigator in multiple large randomised controlled trials, leading to over 70 Pubmed registered publications. He has performed a PhD on the multimodal treatment of locally advanced rectal and locally recurrent rectal cancer (ISBN 90-367-1418-4).
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Lectures by this speaker
Sunday, 2022-11-27
Latest Advances in Surgical Techniques for Colorectal Cancer
14:40 - 15:00
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Dr. Diaeddine Trad | United Arab Emirates

Dr. Diaeddine Trad
Consultant Physician, Oncology Clinic
Dr. Diaeddine Trad is a Consultant of Medical Oncology, at Tawam Hospital, in Al Ain, UAE. He is a member of the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). He is an investigator in several ongoing clinical trials. Dr. Trad is certified as a specialist in internal medicine, hematology and oncology by the Lebanese Ministry of Health. His research interests include; non-small cell lung adenocarcinoma and locally advanced breast cancer. Dr. Trad was a speaker in many international conferences and forums.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Saturday, 2022-11-26
Session 5: Lung Cancer Session
14:00 - 15:40
Sunday, 2022-11-27
Session 3: Gastrointestinal Session
11:00 - 14:00
Saturday, 2022-11-26
Session 7: Lung Cancer Session
15:40 - 17:30
Lectures by this speaker
Saturday, 2022-11-26
Real world effectiveness data for MBC patients – Supported by Pfizer
12:20 - 12:40
Saturday, 2022-11-26
Panel Discussion and Q&A
13:00 - 13:10
Saturday, 2022-11-26
Panel Discussion and Q&A’s
15:00 - 15:10
Saturday, 2022-11-26
Closing Remarks
17:10 - 17:20
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Sunday, 2022-11-27
Meeting Close
16:35 - 16:40
Sunday, 2022-11-27
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly
12:20 - 12:40
16:00 - 16:40
Meeting Close
Dr. Diaeddine Trad | United Arab Emirates

Dr. Diaeddine Trad
Consultant Physician, Oncology Clinic
Dr. Diaeddine Trad is a Consultant of Medical Oncology, at Tawam Hospital, in Al Ain, UAE. He is a member of the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). He is an investigator in several ongoing clinical trials. Dr. Trad is certified as a specialist in internal medicine, hematology and oncology by the Lebanese Ministry of Health. His research interests include; non-small cell lung adenocarcinoma and locally advanced breast cancer. Dr. Trad was a speaker in many international conferences and forums.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Saturday, 2022-11-26
Session 5: Lung Cancer Session
14:00 - 15:40
Sunday, 2022-11-27
Session 3: Gastrointestinal Session
11:00 - 14:00
Saturday, 2022-11-26
Session 7: Lung Cancer Session
15:40 - 17:30
Lectures by this speaker
Saturday, 2022-11-26
Real world effectiveness data for MBC patients – Supported by Pfizer
12:20 - 12:40
Saturday, 2022-11-26
Panel Discussion and Q&A
13:00 - 13:10
Saturday, 2022-11-26
Panel Discussion and Q&A’s
15:00 - 15:10
Saturday, 2022-11-26
Closing Remarks
17:10 - 17:20
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Sunday, 2022-11-27
Meeting Close
16:35 - 16:40
Sunday, 2022-11-27
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly
12:20 - 12:40
16:35 - 16:40
Session 2: Genitourinary malignancies- I
Dr. Jawaher Ali Ansari | United Arab Emirates

Dr. Jawaher Ali Ansari
Acting Chief, Oncology Clinic | United Arab Emirates
Dr Jawaher Ansari completed his Clinical Oncology specialist training in Birmingham, UK and worked as a Consultant at the Beatson Cancer Centre in Glasgow, the second largest cancer center in the UK, prior to moving to the Middle East. Dr Ansari has been a principal investigator for several international clinical trials and has authored several peer-reviewed publications and textbook chapters. He has a specialist interest in Urology, Breast and Lung cancers.
Sessions by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Lectures by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Chairperson:
Dr. Aftab Ahmed Bhatti | United Arab Emirates

Dr. Aftab Ahmed Bhatti
Consultant Physician, Urology Clinic | United Arab Emirates
Dr Aftab Ahmad Bhatti has recently joined Tawam Hospital as a Consultant Urological Surgeon, after working in the United Kingdom for more than 25 years. The main focus of his work is Urological Oncology, Minimally Invasive Robotic Surgery and Laparoscopic surgery. Dr Aftab A Bhatti graduated from the University of Punjab, Rawalpindi Medical College, Pakistan. He completed his higher urological training from the Northern Deanery, Newcastle upon Tyne, UK. Dr Aftab Bhatti has published over 40 peer reviewed publications and his area of research interest includes kidney and prostate cancer. the area of his interest includes active surveillance for the low risk prostate cancer, surgical anatomy of prostate, refinements to surgical techniques for robotic assisted radical prostatectomy and surgical outcomes of the high risk prostate cancer and prognostic markers for the kidney cancer.
Sessions by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Lectures by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Chairperson:
Dr. Muwafak Salman | United Arab Emirates

Dr. Muwafak Salman
Division Chief - Urology Clinic - Medical Affairs | United Arab Emirates
Dr. Muwafak Salman, Consultant Urology, Andrology, Infertility and Men’s Health and Chief of Urology Department at Tawam Hospital. Dr. Salman has more than 16 years of experience ,in addition to, being certified by the Arab Board of Medical Specialties, with specialization in Surgery and the European board of Urology. He has completed his fellowship from the Royal College of Surgeons in Ireland, as well as, being a member in the American Urological Association.
Sessions by this speaker
Thursday,
-
Lectures by this speaker
Thursday,
-
08:30 - 11:00
Welcome Note
Dr. Jawaher Ali Ansari | United Arab Emirates

Dr. Jawaher Ali Ansari
Acting Chief, Oncology Clinic
Dr Jawaher Ansari completed his Clinical Oncology specialist training in Birmingham, UK and worked as a Consultant at the Beatson Cancer Centre in Glasgow, the second largest cancer center in the UK, prior to moving to the Middle East. Dr Ansari has been a principal investigator for several international clinical trials and has authored several peer-reviewed publications and textbook chapters. He has a specialist interest in Urology, Breast and Lung cancers.
Sessions by this speaker
Friday, 2022-11-25
Scientific Committee
00:00 - 23:55
Friday, 2022-11-25
Organizing Committee
00:00 - 23:55
Friday, 2022-11-25
Session 1 Plenary
08:30 - 11:00
Friday, 2022-11-25
Session 6: Abstract presentations
15:40 - 16:50
Sunday, 2022-11-27
Session 2: Genitourinary malignancies- I
08:30 - 11:00
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Lectures by this speaker
Friday, 2022-11-25
Panel Discussion
09:40 - 10:00
Sunday, 2022-11-27
Welcome Note
08:30 - 08:32
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Intensifying Therapy Earlier in the Disease Course , Are We Doing Enough to Improve Outcomes? - Supported by Bayer
10:00 - 10:20
Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen
10:20 - 10:40
Sunday, 2022-11-27
Padcev® - Evolving landscape in the management of La/mUC - Supported by Astellas
12:30 - 12:50
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Sunday, 2022-11-27
Updates on the Management of mRCC and Role of Cabozantinib in the 1st line Treatment - Supported by IPSEN
16:25 - 16:45
Friday, 2022-11-25
30 years of Innovation & commitment to enhancing patient experience- Neulastim Onpro - Supported by KyowaKirin
15:40 - 15:50
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
08:30 - 08:32
Variations in Surgical Techniques during Robot Assisted Radical Prostatectomy an Individualised Approach
Dr. Aftab Ahmed Bhatti | United Arab Emirates

Dr. Aftab Ahmed Bhatti
Consultant Physician, Urology Clinic
Dr Aftab Ahmad Bhatti has recently joined Tawam Hospital as a Consultant Urological Surgeon, after working in the United Kingdom for more than 25 years. The main focus of his work is Urological Oncology, Minimally Invasive Robotic Surgery and Laparoscopic surgery. Dr Aftab A Bhatti graduated from the University of Punjab, Rawalpindi Medical College, Pakistan. He completed his higher urological training from the Northern Deanery, Newcastle upon Tyne, UK. Dr Aftab Bhatti has published over 40 peer reviewed publications and his area of research interest includes kidney and prostate cancer. the area of his interest includes active surveillance for the low risk prostate cancer, surgical anatomy of prostate, refinements to surgical techniques for robotic assisted radical prostatectomy and surgical outcomes of the high risk prostate cancer and prognostic markers for the kidney cancer.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Sunday, 2022-11-27
Session 2: Genitourinary malignancies- I
08:30 - 11:00
Sunday, 2022-11-27
Session 4: Genitourinary malignancies II - Kidney & Bladder Cancers
11:00 - 14:00
Lectures by this speaker
Sunday, 2022-11-27
Variations in Surgical Techniques during Robot Assisted Radical Prostatectomy an Individualised Approach
08:30 - 08:50
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
08:30 - 08:50
Evolving role of SBRT in Localised Prostate cancer

Dr. Paul Kelly
Consultant Radiation Oncologist
Dr Paul Kelly is a graduate of University College Cork and completed General Professional Training in medicine at the Mater Hospital, Dublin. Having acquired Membership of the Royal College of Physicians he completed specialist training in Radiation Oncology at St Luke’s Hospital in Dublin. He became a Fellow of the Faculty of Radiology at the Royal College of Surgeons in Ireland in 2008 and, thereafter, completed a 2-year Clinical Fellowship in Stereotactic Radiosurgery at Brigham and Women’s Hospital/Dana-Farber Cancer Institute in Boston, Massachusetts. Based in Cork since 2011 as a Consultant Radiation Oncologist he is active in clinical research and co-chairs the GU disease-specific subgroup (DSSG) of Cancer Trials Ireland. His chief interests include prostate cancer, brain tumours, stereotactic radiotherapy and prostate seed brachytherapy. He took up a position as Medical Director of the new radiation oncology facility at the Bon Secours Radiotherapy Centre joint venture with University of Pittsburgh Medical Centre (UPMC) Hillman Cancer Centre in 2019.
Lectures by this speaker
Saturday, 2022-11-26
Lung SABR: A Practical Guide for the Radiation Oncologist
14:20 - 14:40
Saturday, 2022-11-26
Panel Discussion
15:20 - 15:30
Sunday, 2022-11-27
Evolving role of SBRT in Localised Prostate cancer
08:50 - 09:10
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
08:50 - 09:10
Triple combination therapy is the recommended option for all patients with mCSPC- FOR

Dr. Bertrand Tombal
Professor and Chairman
"Bertrand Tombal is the Chairman of the Department of Surgery and Full Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium. He is the Past President of the European Organization for Research and Treatment of Cancer (EORTC), the leading European academic research organization in the field of cancer. He has both a basic science and a clinical interest in urological oncology, particularly in the field of prostate and bladder cancer. Professor Tombal obtained his MD in 1990 and his PhD in 2003, both from the Université catholique de Louvain. During his PhD, he studied the mechanisms involved in apoptosis of prostate cancer cells and the modulation of apoptosis by growth factors. He completed part of his basic sciences training at Johns Hopkins University, Baltimore, MD, USA. Professor Tombal’s primary clinical interest is the treatment of advanced stages of prostate cancer, and particularly hormonal treatment and development of new biological agents. He is heading the urooncology division at the Université catholique de Louvain where he is coordinating several trials in this research area. In addition, Professor Tombal has authored more than 300 published papers, books, and book chapters. He has presented at numerous national and international conferences and has been the recipient of various awards for his research in the field of urology, including the European Association of Urology thesis award, which he received in 2003."
Lectures by this speaker
Sunday, 2022-11-27
Triple combination therapy is the recommended option for all patients with mCSPC- FOR
09:10 - 09:30
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Intensifying Therapy Earlier in the Disease Course , Are We Doing Enough to Improve Outcomes? - Supported by Bayer
10:00 - 10:20
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
09:10 - 09:30
Triple combination therapy is the recommended option for all patients with mCSPC- AGAINST
Prof. Rob Jones | United Kingdom

Prof. Rob Jones
Director, CRUK Clinical Trials Unit
Professor Jones is Director, CRUK Clinical Trials Unit, Beatson West of Scotland Cancer Centre. After undergraduate training at the Universities of Oxford and Edinburgh, Rob moved to Glasgow to train in internal medicine and then Medical Oncology. He completed PhD in the Frame Lab at the Beatson Institute for Cancer research, where he studied the role of Src kinase in metastatic progression. From 2003 to 2005 he was seconded to the department of Experimental (Discovery) Medicine at Alderley Park (AstraZeneca plc) where he provided translational medicine input to a number of early oncology projects in the invasion and metastasis biological effect area.
Lectures by this speaker
Sunday, 2022-11-27
Triple combination therapy is the recommended option for all patients with mCSPC- AGAINST
09:30 - 09:50
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Metastatic Renal Cell Carcinoma- Challenges in First-line Decision Making for Metastatic Clear Cell RCC
11:00 - 11:20
Sunday, 2022-11-27
Padcev® - Evolving landscape in the management of La/mUC - Supported by Astellas
12:30 - 12:50
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
09:30 - 09:50
Panel Discussion and Q&A’s + Voting

Dr. Paul Kelly
Consultant Radiation Oncologist
Dr Paul Kelly is a graduate of University College Cork and completed General Professional Training in medicine at the Mater Hospital, Dublin. Having acquired Membership of the Royal College of Physicians he completed specialist training in Radiation Oncology at St Luke’s Hospital in Dublin. He became a Fellow of the Faculty of Radiology at the Royal College of Surgeons in Ireland in 2008 and, thereafter, completed a 2-year Clinical Fellowship in Stereotactic Radiosurgery at Brigham and Women’s Hospital/Dana-Farber Cancer Institute in Boston, Massachusetts. Based in Cork since 2011 as a Consultant Radiation Oncologist he is active in clinical research and co-chairs the GU disease-specific subgroup (DSSG) of Cancer Trials Ireland. His chief interests include prostate cancer, brain tumours, stereotactic radiotherapy and prostate seed brachytherapy. He took up a position as Medical Director of the new radiation oncology facility at the Bon Secours Radiotherapy Centre joint venture with University of Pittsburgh Medical Centre (UPMC) Hillman Cancer Centre in 2019.
Lectures by this speaker
Saturday, 2022-11-26
Lung SABR: A Practical Guide for the Radiation Oncologist
14:20 - 14:40
Saturday, 2022-11-26
Panel Discussion
15:20 - 15:30
Sunday, 2022-11-27
Evolving role of SBRT in Localised Prostate cancer
08:50 - 09:10
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00

Dr. Bertrand Tombal
Professor and Chairman
"Bertrand Tombal is the Chairman of the Department of Surgery and Full Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium. He is the Past President of the European Organization for Research and Treatment of Cancer (EORTC), the leading European academic research organization in the field of cancer. He has both a basic science and a clinical interest in urological oncology, particularly in the field of prostate and bladder cancer. Professor Tombal obtained his MD in 1990 and his PhD in 2003, both from the Université catholique de Louvain. During his PhD, he studied the mechanisms involved in apoptosis of prostate cancer cells and the modulation of apoptosis by growth factors. He completed part of his basic sciences training at Johns Hopkins University, Baltimore, MD, USA. Professor Tombal’s primary clinical interest is the treatment of advanced stages of prostate cancer, and particularly hormonal treatment and development of new biological agents. He is heading the urooncology division at the Université catholique de Louvain where he is coordinating several trials in this research area. In addition, Professor Tombal has authored more than 300 published papers, books, and book chapters. He has presented at numerous national and international conferences and has been the recipient of various awards for his research in the field of urology, including the European Association of Urology thesis award, which he received in 2003."
Lectures by this speaker
Sunday, 2022-11-27
Triple combination therapy is the recommended option for all patients with mCSPC- FOR
09:10 - 09:30
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Intensifying Therapy Earlier in the Disease Course , Are We Doing Enough to Improve Outcomes? - Supported by Bayer
10:00 - 10:20
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
Prof. Rob Jones | United Kingdom

Prof. Rob Jones
Director, CRUK Clinical Trials Unit
Professor Jones is Director, CRUK Clinical Trials Unit, Beatson West of Scotland Cancer Centre. After undergraduate training at the Universities of Oxford and Edinburgh, Rob moved to Glasgow to train in internal medicine and then Medical Oncology. He completed PhD in the Frame Lab at the Beatson Institute for Cancer research, where he studied the role of Src kinase in metastatic progression. From 2003 to 2005 he was seconded to the department of Experimental (Discovery) Medicine at Alderley Park (AstraZeneca plc) where he provided translational medicine input to a number of early oncology projects in the invasion and metastasis biological effect area.
Lectures by this speaker
Sunday, 2022-11-27
Triple combination therapy is the recommended option for all patients with mCSPC- AGAINST
09:30 - 09:50
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Metastatic Renal Cell Carcinoma- Challenges in First-line Decision Making for Metastatic Clear Cell RCC
11:00 - 11:20
Sunday, 2022-11-27
Padcev® - Evolving landscape in the management of La/mUC - Supported by Astellas
12:30 - 12:50
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Dr. Muwafak Salman | United Arab Emirates

Dr. Muwafak Salman
Division Chief - Urology Clinic - Medical Affairs
Dr. Muwafak Salman, Consultant Urology, Andrology, Infertility and Men’s Health and Chief of Urology Department at Tawam Hospital. Dr. Salman has more than 16 years of experience ,in addition to, being certified by the Arab Board of Medical Specialties, with specialization in Surgery and the European board of Urology. He has completed his fellowship from the Royal College of Surgeons in Ireland, as well as, being a member in the American Urological Association.
Sessions by this speaker
Sunday, 2022-11-27
Session 2: Genitourinary malignancies- I
08:30 - 11:00
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Dr. Jawaher Ali Ansari | United Arab Emirates

Dr. Jawaher Ali Ansari
Acting Chief, Oncology Clinic
Dr Jawaher Ansari completed his Clinical Oncology specialist training in Birmingham, UK and worked as a Consultant at the Beatson Cancer Centre in Glasgow, the second largest cancer center in the UK, prior to moving to the Middle East. Dr Ansari has been a principal investigator for several international clinical trials and has authored several peer-reviewed publications and textbook chapters. He has a specialist interest in Urology, Breast and Lung cancers.
Sessions by this speaker
Friday, 2022-11-25
Scientific Committee
00:00 - 23:55
Friday, 2022-11-25
Organizing Committee
00:00 - 23:55
Friday, 2022-11-25
Session 1 Plenary
08:30 - 11:00
Friday, 2022-11-25
Session 6: Abstract presentations
15:40 - 16:50
Sunday, 2022-11-27
Session 2: Genitourinary malignancies- I
08:30 - 11:00
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Lectures by this speaker
Friday, 2022-11-25
Panel Discussion
09:40 - 10:00
Sunday, 2022-11-27
Welcome Note
08:30 - 08:32
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Intensifying Therapy Earlier in the Disease Course , Are We Doing Enough to Improve Outcomes? - Supported by Bayer
10:00 - 10:20
Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen
10:20 - 10:40
Sunday, 2022-11-27
Padcev® - Evolving landscape in the management of La/mUC - Supported by Astellas
12:30 - 12:50
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Sunday, 2022-11-27
Updates on the Management of mRCC and Role of Cabozantinib in the 1st line Treatment - Supported by IPSEN
16:25 - 16:45
Friday, 2022-11-25
30 years of Innovation & commitment to enhancing patient experience- Neulastim Onpro - Supported by KyowaKirin
15:40 - 15:50
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
Dr. Aftab Ahmed Bhatti | United Arab Emirates

Dr. Aftab Ahmed Bhatti
Consultant Physician, Urology Clinic
Dr Aftab Ahmad Bhatti has recently joined Tawam Hospital as a Consultant Urological Surgeon, after working in the United Kingdom for more than 25 years. The main focus of his work is Urological Oncology, Minimally Invasive Robotic Surgery and Laparoscopic surgery. Dr Aftab A Bhatti graduated from the University of Punjab, Rawalpindi Medical College, Pakistan. He completed his higher urological training from the Northern Deanery, Newcastle upon Tyne, UK. Dr Aftab Bhatti has published over 40 peer reviewed publications and his area of research interest includes kidney and prostate cancer. the area of his interest includes active surveillance for the low risk prostate cancer, surgical anatomy of prostate, refinements to surgical techniques for robotic assisted radical prostatectomy and surgical outcomes of the high risk prostate cancer and prognostic markers for the kidney cancer.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Sunday, 2022-11-27
Session 2: Genitourinary malignancies- I
08:30 - 11:00
Sunday, 2022-11-27
Session 4: Genitourinary malignancies II - Kidney & Bladder Cancers
11:00 - 14:00
Lectures by this speaker
Sunday, 2022-11-27
Variations in Surgical Techniques during Robot Assisted Radical Prostatectomy an Individualised Approach
08:30 - 08:50
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
09:50 - 10:00
Intensifying Therapy Earlier in the Disease Course , Are We Doing Enough to Improve Outcomes? - Supported by Bayer

Dr. Bertrand Tombal
Professor and Chairman
"Bertrand Tombal is the Chairman of the Department of Surgery and Full Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium. He is the Past President of the European Organization for Research and Treatment of Cancer (EORTC), the leading European academic research organization in the field of cancer. He has both a basic science and a clinical interest in urological oncology, particularly in the field of prostate and bladder cancer. Professor Tombal obtained his MD in 1990 and his PhD in 2003, both from the Université catholique de Louvain. During his PhD, he studied the mechanisms involved in apoptosis of prostate cancer cells and the modulation of apoptosis by growth factors. He completed part of his basic sciences training at Johns Hopkins University, Baltimore, MD, USA. Professor Tombal’s primary clinical interest is the treatment of advanced stages of prostate cancer, and particularly hormonal treatment and development of new biological agents. He is heading the urooncology division at the Université catholique de Louvain where he is coordinating several trials in this research area. In addition, Professor Tombal has authored more than 300 published papers, books, and book chapters. He has presented at numerous national and international conferences and has been the recipient of various awards for his research in the field of urology, including the European Association of Urology thesis award, which he received in 2003."
Lectures by this speaker
Sunday, 2022-11-27
Triple combination therapy is the recommended option for all patients with mCSPC- FOR
09:10 - 09:30
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Intensifying Therapy Earlier in the Disease Course , Are We Doing Enough to Improve Outcomes? - Supported by Bayer
10:00 - 10:20
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
Dr. Jawaher Ali Ansari | United Arab Emirates

Dr. Jawaher Ali Ansari
Acting Chief, Oncology Clinic
Dr Jawaher Ansari completed his Clinical Oncology specialist training in Birmingham, UK and worked as a Consultant at the Beatson Cancer Centre in Glasgow, the second largest cancer center in the UK, prior to moving to the Middle East. Dr Ansari has been a principal investigator for several international clinical trials and has authored several peer-reviewed publications and textbook chapters. He has a specialist interest in Urology, Breast and Lung cancers.
Sessions by this speaker
Friday, 2022-11-25
Scientific Committee
00:00 - 23:55
Friday, 2022-11-25
Organizing Committee
00:00 - 23:55
Friday, 2022-11-25
Session 1 Plenary
08:30 - 11:00
Friday, 2022-11-25
Session 6: Abstract presentations
15:40 - 16:50
Sunday, 2022-11-27
Session 2: Genitourinary malignancies- I
08:30 - 11:00
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Lectures by this speaker
Friday, 2022-11-25
Panel Discussion
09:40 - 10:00
Sunday, 2022-11-27
Welcome Note
08:30 - 08:32
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Intensifying Therapy Earlier in the Disease Course , Are We Doing Enough to Improve Outcomes? - Supported by Bayer
10:00 - 10:20
Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen
10:20 - 10:40
Sunday, 2022-11-27
Padcev® - Evolving landscape in the management of La/mUC - Supported by Astellas
12:30 - 12:50
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Sunday, 2022-11-27
Updates on the Management of mRCC and Role of Cabozantinib in the 1st line Treatment - Supported by IPSEN
16:25 - 16:45
Friday, 2022-11-25
30 years of Innovation & commitment to enhancing patient experience- Neulastim Onpro - Supported by KyowaKirin
15:40 - 15:50
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
10:00 - 10:20
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen
Dr. Jawaher Ali Ansari | United Arab Emirates

Dr. Jawaher Ali Ansari
Acting Chief, Oncology Clinic
Dr Jawaher Ansari completed his Clinical Oncology specialist training in Birmingham, UK and worked as a Consultant at the Beatson Cancer Centre in Glasgow, the second largest cancer center in the UK, prior to moving to the Middle East. Dr Ansari has been a principal investigator for several international clinical trials and has authored several peer-reviewed publications and textbook chapters. He has a specialist interest in Urology, Breast and Lung cancers.
Sessions by this speaker
Friday, 2022-11-25
Scientific Committee
00:00 - 23:55
Friday, 2022-11-25
Organizing Committee
00:00 - 23:55
Friday, 2022-11-25
Session 1 Plenary
08:30 - 11:00
Friday, 2022-11-25
Session 6: Abstract presentations
15:40 - 16:50
Sunday, 2022-11-27
Session 2: Genitourinary malignancies- I
08:30 - 11:00
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Lectures by this speaker
Friday, 2022-11-25
Panel Discussion
09:40 - 10:00
Sunday, 2022-11-27
Welcome Note
08:30 - 08:32
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Intensifying Therapy Earlier in the Disease Course , Are We Doing Enough to Improve Outcomes? - Supported by Bayer
10:00 - 10:20
Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen
10:20 - 10:40
Sunday, 2022-11-27
Padcev® - Evolving landscape in the management of La/mUC - Supported by Astellas
12:30 - 12:50
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Sunday, 2022-11-27
Updates on the Management of mRCC and Role of Cabozantinib in the 1st line Treatment - Supported by IPSEN
16:25 - 16:45
Friday, 2022-11-25
30 years of Innovation & commitment to enhancing patient experience- Neulastim Onpro - Supported by KyowaKirin
15:40 - 15:50
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
Dr. Emad Dawoud | United Arab Emirates

Dr. Emad Dawoud
Consultant Physician, Oncology Clinic
Dr. Emad Dawoud is a Consultant Medical Oncologist in Oncology department at Tawam hospital UAE, and Assistant professor of clinical oncology in Al Azhar University Cairo, Egypt. Dr. Dawoud has been principal investigator and co- investigator for more than 50 clinical trials and abstract published per reviewed journals and he is a member of various associations such as ASCO, ESMO, ESTRO.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Friday, 2022-11-25
Session 3: Gynaecological cancers
11:20 - 14:00
Friday, 2022-11-25
Session 5: Gynaecological Cancers
14:00 - 15:40
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Saturday, 2022-11-26
Session 1: Early Breast Cancer Session
08:30 - 11:00
Lectures by this speaker
Friday, 2022-11-25
Management of endometrial cancer in the molecular era
15:40 - 16:00
Friday, 2022-11-25
Panel Discussion- Q&A
15:00 - 15:20
Friday, 2022-11-25
Endometrial Cancer - Case Based Discussion
12:00 - 12:30
Friday, 2022-11-25
Panel Discussion
12:30 - 12:40
Friday, 2022-11-25
Panel Discussion- Q&A
16:20 - 16:30
Saturday, 2022-11-26
Recent Advances in Systemic Therapy in Resected Lung Cancer - Supported by Roche
14:40 - 15:00
Saturday, 2022-11-26
Panel Discussion and Q&A’s
15:00 - 15:10
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen
10:20 - 10:40
Sunday, 2022-11-27
Case Presentation Lung Cancer
14:00 - 14:45
Sunday, 2022-11-27
Optimizing the 1st line treatment in mCRC - Supported by Merck
12:00 - 12:20
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
Saturday, 2022-11-26
Early Breast Cancer and the Use of Abemacilcib to Prevent Recurrence in Patients with HR+, HER2- with High Risk of Recurrence - Supported by Lilly
09:50 - 10:10
10:20 - 10:40
Panel Discussion and Q & A

Dr. Bertrand Tombal
Professor and Chairman
"Bertrand Tombal is the Chairman of the Department of Surgery and Full Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium. He is the Past President of the European Organization for Research and Treatment of Cancer (EORTC), the leading European academic research organization in the field of cancer. He has both a basic science and a clinical interest in urological oncology, particularly in the field of prostate and bladder cancer. Professor Tombal obtained his MD in 1990 and his PhD in 2003, both from the Université catholique de Louvain. During his PhD, he studied the mechanisms involved in apoptosis of prostate cancer cells and the modulation of apoptosis by growth factors. He completed part of his basic sciences training at Johns Hopkins University, Baltimore, MD, USA. Professor Tombal’s primary clinical interest is the treatment of advanced stages of prostate cancer, and particularly hormonal treatment and development of new biological agents. He is heading the urooncology division at the Université catholique de Louvain where he is coordinating several trials in this research area. In addition, Professor Tombal has authored more than 300 published papers, books, and book chapters. He has presented at numerous national and international conferences and has been the recipient of various awards for his research in the field of urology, including the European Association of Urology thesis award, which he received in 2003."
Lectures by this speaker
Sunday, 2022-11-27
Triple combination therapy is the recommended option for all patients with mCSPC- FOR
09:10 - 09:30
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Intensifying Therapy Earlier in the Disease Course , Are We Doing Enough to Improve Outcomes? - Supported by Bayer
10:00 - 10:20
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
Dr. Jawaher Ali Ansari | United Arab Emirates

Dr. Jawaher Ali Ansari
Acting Chief, Oncology Clinic
Dr Jawaher Ansari completed his Clinical Oncology specialist training in Birmingham, UK and worked as a Consultant at the Beatson Cancer Centre in Glasgow, the second largest cancer center in the UK, prior to moving to the Middle East. Dr Ansari has been a principal investigator for several international clinical trials and has authored several peer-reviewed publications and textbook chapters. He has a specialist interest in Urology, Breast and Lung cancers.
Sessions by this speaker
Friday, 2022-11-25
Scientific Committee
00:00 - 23:55
Friday, 2022-11-25
Organizing Committee
00:00 - 23:55
Friday, 2022-11-25
Session 1 Plenary
08:30 - 11:00
Friday, 2022-11-25
Session 6: Abstract presentations
15:40 - 16:50
Sunday, 2022-11-27
Session 2: Genitourinary malignancies- I
08:30 - 11:00
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Lectures by this speaker
Friday, 2022-11-25
Panel Discussion
09:40 - 10:00
Sunday, 2022-11-27
Welcome Note
08:30 - 08:32
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Intensifying Therapy Earlier in the Disease Course , Are We Doing Enough to Improve Outcomes? - Supported by Bayer
10:00 - 10:20
Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen
10:20 - 10:40
Sunday, 2022-11-27
Padcev® - Evolving landscape in the management of La/mUC - Supported by Astellas
12:30 - 12:50
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Sunday, 2022-11-27
Updates on the Management of mRCC and Role of Cabozantinib in the 1st line Treatment - Supported by IPSEN
16:25 - 16:45
Friday, 2022-11-25
30 years of Innovation & commitment to enhancing patient experience- Neulastim Onpro - Supported by KyowaKirin
15:40 - 15:50
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
Dr. Emad Dawoud | United Arab Emirates

Dr. Emad Dawoud
Consultant Physician, Oncology Clinic
Dr. Emad Dawoud is a Consultant Medical Oncologist in Oncology department at Tawam hospital UAE, and Assistant professor of clinical oncology in Al Azhar University Cairo, Egypt. Dr. Dawoud has been principal investigator and co- investigator for more than 50 clinical trials and abstract published per reviewed journals and he is a member of various associations such as ASCO, ESMO, ESTRO.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Friday, 2022-11-25
Session 3: Gynaecological cancers
11:20 - 14:00
Friday, 2022-11-25
Session 5: Gynaecological Cancers
14:00 - 15:40
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Saturday, 2022-11-26
Session 1: Early Breast Cancer Session
08:30 - 11:00
Lectures by this speaker
Friday, 2022-11-25
Management of endometrial cancer in the molecular era
15:40 - 16:00
Friday, 2022-11-25
Panel Discussion- Q&A
15:00 - 15:20
Friday, 2022-11-25
Endometrial Cancer - Case Based Discussion
12:00 - 12:30
Friday, 2022-11-25
Panel Discussion
12:30 - 12:40
Friday, 2022-11-25
Panel Discussion- Q&A
16:20 - 16:30
Saturday, 2022-11-26
Recent Advances in Systemic Therapy in Resected Lung Cancer - Supported by Roche
14:40 - 15:00
Saturday, 2022-11-26
Panel Discussion and Q&A’s
15:00 - 15:10
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen
10:20 - 10:40
Sunday, 2022-11-27
Case Presentation Lung Cancer
14:00 - 14:45
Sunday, 2022-11-27
Optimizing the 1st line treatment in mCRC - Supported by Merck
12:00 - 12:20
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
Saturday, 2022-11-26
Early Breast Cancer and the Use of Abemacilcib to Prevent Recurrence in Patients with HR+, HER2- with High Risk of Recurrence - Supported by Lilly
09:50 - 10:10
10:40 - 10:50
COFFEE BREAK
10:50 - 11:00
Session 4: Genitourinary malignancies II - Kidney & Bladder Cancers
Dr. Deborah Mukherjee | United Arab Emirates

Dr. Deborah Mukherjee
Consultant Medical Oncologist | United Arab Emirates
Dr Mukherji completed her advanced specialty training in Medical Oncology at Guys and St Thomas’s NHS Foundation Trust, London UK and was awarded a Post-Graduate Diploma in Oncology from the Institute of Cancer Research, University of London in 2011. Dr Deborah Mukherji joined the faculty of the American University of Beirut Medical Center in June 2012 as a medical oncologist with a special interest in genitourinary and gastrointestinal oncology and leads the Cancer In Conflict Workstream of the Research for Cancer in Conflict (R4HC MENA), is a Commissioner for the Lancet Commission on Women and Cancer and a faculty member for the European Society of Medical Oncology. Dr Mukherji recently joined the Clemenceau Medical Center Dubai as a consultant medical oncologist and continues her collaborative international academic and educational activities.
Sessions by this speaker
Thursday,
-
Lectures by this speaker
Thursday,
-
Chairperson:
Dr. Syed Tirmazy | United Arab Emirates

Dr. Syed Tirmazy
Consultant Clinical Oncologist | United Arab Emirates
"Dr Syed Hammad Tirmazy is a Consultant Clinical Oncologist and Head of Oncology at Dubai Hospital, DHA. He has substantive experience in managing adult solid cancers and has been involved in multiple international clinical trials. Before moving to Dubai in 2016, he was working as Consultant Clinical Oncologist in west midlands region UK. After completing his graduation, he moved to UK in 2003, he initially completed internal medicine training and MRCP and subsequently attained training in Clinical Oncology and worked in internationally renowned oncology centers in UK including Queen Elizabeth Hospital Birmingham. He completed Master’s in Clinical Oncology from university of Birmingham, FRCR Clinical Oncology from RCR London and has CCT in Clinical Oncology. He also attained FRCP Glasgow. "
Sessions by this speaker
Thursday,
-
Lectures by this speaker
Thursday,
-
Chairperson:
Dr. Aftab Ahmed Bhatti | United Arab Emirates

Dr. Aftab Ahmed Bhatti
Consultant Physician, Urology Clinic | United Arab Emirates
Dr Aftab Ahmad Bhatti has recently joined Tawam Hospital as a Consultant Urological Surgeon, after working in the United Kingdom for more than 25 years. The main focus of his work is Urological Oncology, Minimally Invasive Robotic Surgery and Laparoscopic surgery. Dr Aftab A Bhatti graduated from the University of Punjab, Rawalpindi Medical College, Pakistan. He completed his higher urological training from the Northern Deanery, Newcastle upon Tyne, UK. Dr Aftab Bhatti has published over 40 peer reviewed publications and his area of research interest includes kidney and prostate cancer. the area of his interest includes active surveillance for the low risk prostate cancer, surgical anatomy of prostate, refinements to surgical techniques for robotic assisted radical prostatectomy and surgical outcomes of the high risk prostate cancer and prognostic markers for the kidney cancer.
Sessions by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Lectures by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Chairperson:
Dr. Yasser Farahat | United Arab Emirates

Dr. Yasser Farahat
Chairman | United Arab Emirates
"Dr. Yasser Farahat currently serves as Professor of Urology at Tanta University, Egypt, a Clinical Tutor at Edinburg University, UK, and a Fellow of the Royal College of Surgeons, UK. He is a Consultant Urologist at the Ministry of Health and Prevention UAE and a Fellow of the European Board of Urology (FEBU). He is acting as a Senior Consultant of Urology at Sheikh Khalifa General Hospital (SKGH-UAQ), UAE. His special interests & research include minimally invasive surgery, Endo-urology, Robotic Assisted FURS, Reconstructive Urology, and Andrology. He completed his MD in 2004 at Tanta University, Egypt. He had been awarded several prizes including the Best Research and Presentation at The First Eastern Mediterranean Meeting of European Association of Urology in 2007 and The Best Research Poster Presentation at the 25th annual EAU Congress in 2010. He is one of the worldwide initiators of using the robotic-assisted RIRS since the invention of the Roboflex and improving the utilization of flexible ureteroscopy in renal calculi management. He is also, a reviewer of several international journals. He has published over 35 international and local publications and has presented at 90 conferences worldwide. Dr. Farahat is an active member of many international urological associations and societies including, The European Association of Urology (EAU), Société Internationale D’Urologie (SIU), Endourological Society and he is currently the head of the scientific committee of Emirates Urological Society (EUS), Cochair of the scientific committee of Urological Association of Asia (UAA), Secretary-General of Arab Association of Urology (AAU) and Chairman of Arab School of Urology. "
Sessions by this speaker
Thursday,
-
Metastatic Renal Cell Carcinoma- Challenges in First-line Decision Making for Metastatic Clear Cell RCC
Prof. Rob Jones | United Kingdom

Prof. Rob Jones
Director, CRUK Clinical Trials Unit
Professor Jones is Director, CRUK Clinical Trials Unit, Beatson West of Scotland Cancer Centre. After undergraduate training at the Universities of Oxford and Edinburgh, Rob moved to Glasgow to train in internal medicine and then Medical Oncology. He completed PhD in the Frame Lab at the Beatson Institute for Cancer research, where he studied the role of Src kinase in metastatic progression. From 2003 to 2005 he was seconded to the department of Experimental (Discovery) Medicine at Alderley Park (AstraZeneca plc) where he provided translational medicine input to a number of early oncology projects in the invasion and metastasis biological effect area.
Lectures by this speaker
Sunday, 2022-11-27
Triple combination therapy is the recommended option for all patients with mCSPC- AGAINST
09:30 - 09:50
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Metastatic Renal Cell Carcinoma- Challenges in First-line Decision Making for Metastatic Clear Cell RCC
11:00 - 11:20
Sunday, 2022-11-27
Padcev® - Evolving landscape in the management of La/mUC - Supported by Astellas
12:30 - 12:50
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
11:00 - 11:20
Dual Immunotherapy Approach in 1L RCC Treatment - Supported by BMS
Dr. Nouri Bennini | United Arab Emirates

Dr. Nouri Bennini
Consultant Physician, Oncology Clinic
Dr.Nouri Bennini is a Consultant Physician, Oncology Clinic at Tawam Hospital.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Saturday, 2022-11-26
Session 1: Early Breast Cancer Session
08:30 - 11:00
Sunday, 2022-11-27
Session 5: Gastrointestinal Session
14:00 - 16:40
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s
10:10 - 10:30
Saturday, 2022-11-26
Beyond Covid 19 Vaccination : Evusheld (Tixagevimab and Cilgevimab ) for the Prevention and Treatment of Covid 19 among the High Risk Patients - Supported by AstraZeneca
15:10 - 15:30
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Dual Immunotherapy Approach in 1L RCC Treatment - Supported by BMS
11:20 - 11:50
Sunday, 2022-11-27
Case Presentation Breast Cancer
14:45 - 15:30
Sunday, 2022-11-27
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly
12:20 - 12:40
11:20 - 11:50
Looking in to the Future of Treatment for Advanced Urothelial Cancers
Prof. Syed Hussain | United Kingdom

Prof. Syed Hussain
Professor and Consultant in Medical Oncology
"Professor Hussain graduated from Dow Medical College Karachi in 1994. He completed his general medical professional training in UK. He did his Doctorate in Oncology from University of Birmingham. He then completed his Medical oncology training in Birmingham, United Kingdom and received his certification and specialist registration in Medical oncology. Professor Hussain is Professor and Consultant in Medical Oncology at the University of Sheffield and Sheffield Teaching Hospitals NHS Trust. His major areas of interest are management of urological cancers, clinical trials, early drug development and translational medicine. He has set up large number of clinical trials from early phase to late phase studies during his career. His work on organ preservation in bladder cancer moved all the way from an early phase I study (Hussain et al Annals of Oncology 2001) to phase II efficacy study (Hussain et al BJC 2004) that led to a Cancer Research UK funded study BC2001 trial that was reported in New England Journal of Medicine (James, Hussain, Hall et al April 2012). This study has now changed the standard of care for patients with muscle invasive bladder cancer opting for organ preservation treatment. Professor Hussain is principal investigator of number of studies in urological cancers. He is a chief investigator of a national randomised placebo-controlled phase II neo-adjuvant study in muscle invasive bladder cancer. He served as chief investigator of various early phase trials, and translational studies. Professor Hussain has authored over 105 peer-reviewed publications including 4 book chapters in textbooks of oncology. His Google scholar H-index is 37 with over 8300 citations. He has published in high impact journals including New England Journal of medicine, Lancet, Lancet Oncology, JAMA, JAMA Oncology, Journal of Clinical oncology, European Urology, Annals of Oncology, Nature communications, Clinical Cancer Research, British journal of Cancer. He has been an invited speaker to number of national and international meetings. Professor Hussain has secured funding of over 10 million pounds from funding bodies. "
Lectures by this speaker
Friday, 2022-11-25
Plenary 1: Future of Precision Oncology
08:40 - 09:00
Friday, 2022-11-25
Panel Discussion
09:40 - 10:00
Sunday, 2022-11-27
Looking in to the Future of Treatment for Advanced Urothelial Cancers
11:50 - 12:10
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
11:50 - 12:10
Bladder Cancer Surgery
Dr. Brian Chaplin | United Kingdom

Dr. Brian Chaplin
Consultant Urologist
Mr Chaplin is a consultant urological surgeon; he has worked at James Cook, Middlesbrough and North Tees, Stockton hospitals since April 2011. He was a consultant from 2006-2011 at Bradford Teaching Hospitals and from 2004 to 2006 at Erasmus Medical Centre, Rotterdam, the Netherlands. Mr Chaplin has a special interest in oncological urology. He is especially interested in bladder, prostate and renal cancer. He regularly performs radical surgery for cancer using open and laparoscopic techniques. He has a specific interest in robotic minimally invasive surgery and has been involved in the implementation of the robot for robotic cystectomy since the first case done at James Cook in February 2015. He regularly performs robotic and open radical cystectomies, robotic prostatectomies, open and laparoscopic nephrectomies and nephroureterectomies. He contributes to national audit and research trials. He has presented posters and research data at national and international conferences. He was appointed in April 2017 as multi-disciplinary team lead for the urology cancer centre at James Cook.
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Surgery
12:10 - 12:30
12:10 - 12:30
Padcev® - Evolving landscape in the management of La/mUC - Supported by Astellas
Prof. Rob Jones | United Kingdom

Prof. Rob Jones
Director, CRUK Clinical Trials Unit
Professor Jones is Director, CRUK Clinical Trials Unit, Beatson West of Scotland Cancer Centre. After undergraduate training at the Universities of Oxford and Edinburgh, Rob moved to Glasgow to train in internal medicine and then Medical Oncology. He completed PhD in the Frame Lab at the Beatson Institute for Cancer research, where he studied the role of Src kinase in metastatic progression. From 2003 to 2005 he was seconded to the department of Experimental (Discovery) Medicine at Alderley Park (AstraZeneca plc) where he provided translational medicine input to a number of early oncology projects in the invasion and metastasis biological effect area.
Lectures by this speaker
Sunday, 2022-11-27
Triple combination therapy is the recommended option for all patients with mCSPC- AGAINST
09:30 - 09:50
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Metastatic Renal Cell Carcinoma- Challenges in First-line Decision Making for Metastatic Clear Cell RCC
11:00 - 11:20
Sunday, 2022-11-27
Padcev® - Evolving landscape in the management of La/mUC - Supported by Astellas
12:30 - 12:50
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Dr. Jawaher Ali Ansari | United Arab Emirates

Dr. Jawaher Ali Ansari
Acting Chief, Oncology Clinic
Dr Jawaher Ansari completed his Clinical Oncology specialist training in Birmingham, UK and worked as a Consultant at the Beatson Cancer Centre in Glasgow, the second largest cancer center in the UK, prior to moving to the Middle East. Dr Ansari has been a principal investigator for several international clinical trials and has authored several peer-reviewed publications and textbook chapters. He has a specialist interest in Urology, Breast and Lung cancers.
Sessions by this speaker
Friday, 2022-11-25
Scientific Committee
00:00 - 23:55
Friday, 2022-11-25
Organizing Committee
00:00 - 23:55
Friday, 2022-11-25
Session 1 Plenary
08:30 - 11:00
Friday, 2022-11-25
Session 6: Abstract presentations
15:40 - 16:50
Sunday, 2022-11-27
Session 2: Genitourinary malignancies- I
08:30 - 11:00
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Lectures by this speaker
Friday, 2022-11-25
Panel Discussion
09:40 - 10:00
Sunday, 2022-11-27
Welcome Note
08:30 - 08:32
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Intensifying Therapy Earlier in the Disease Course , Are We Doing Enough to Improve Outcomes? - Supported by Bayer
10:00 - 10:20
Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen
10:20 - 10:40
Sunday, 2022-11-27
Padcev® - Evolving landscape in the management of La/mUC - Supported by Astellas
12:30 - 12:50
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Sunday, 2022-11-27
Updates on the Management of mRCC and Role of Cabozantinib in the 1st line Treatment - Supported by IPSEN
16:25 - 16:45
Friday, 2022-11-25
30 years of Innovation & commitment to enhancing patient experience- Neulastim Onpro - Supported by KyowaKirin
15:40 - 15:50
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
12:30 - 12:50
Panel Discussion
Dr. Deborah Mukherjee | United Arab Emirates

Dr. Deborah Mukherjee
Consultant Medical Oncologist
Dr Mukherji completed her advanced specialty training in Medical Oncology at Guys and St Thomas’s NHS Foundation Trust, London UK and was awarded a Post-Graduate Diploma in Oncology from the Institute of Cancer Research, University of London in 2011. Dr Deborah Mukherji joined the faculty of the American University of Beirut Medical Center in June 2012 as a medical oncologist with a special interest in genitourinary and gastrointestinal oncology and leads the Cancer In Conflict Workstream of the Research for Cancer in Conflict (R4HC MENA), is a Commissioner for the Lancet Commission on Women and Cancer and a faculty member for the European Society of Medical Oncology. Dr Mukherji recently joined the Clemenceau Medical Center Dubai as a consultant medical oncologist and continues her collaborative international academic and educational activities.
Sessions by this speaker
Sunday, 2022-11-27
Session 4: Genitourinary malignancies II - Kidney & Bladder Cancers
11:00 - 14:00
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Dr. Faisal Azam | Saudi Arabia

Dr. Faisal Azam
Consultant Medical Oncologist
Dr Faisal Azam is a consultant medical oncologist at King Fahad specialist Hospital Dammam (KFSHD) and previously worked as a consultant at Betsi cadwaladr university board Hospital in United Kingdom. He has special interest in GU cancers, Gynae cancers, sarcomas and skin cancers. He had completed a formal training in Medical oncology at Clatterbridge cancer centre, Liverpool leading to a CCT and a research training at Oxford University. His qualifications include FRCP, CCT in medical oncology, MRCP-UK, MRCP-Ireland, PG-Dip in Oncology from Birmingham University and PG-Cert in Medical education from Edgehill Liverpool University. He is currently a research in-charge for Oncology, an IRB (Investigational review board) member and FTC (Formulary therapeutics committee) member at KFSHD. He has published more than 40 articles in peer-reviewed journals and did presentations in many international, national and regional oncology conferences.
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Dr. Emad Tashkandi | Saudi Arabia

Dr. Emad Tashkandi
Medical Oncologist
Emad Tashkandi MBBS, ABIM, FRCPC, (Dip) ClinEpi is an Associate Professor at Umm AlQura University and Medical Oncologist at King Abdullah Medical City, Makkah, Saudi Arabia
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Dr. Abdulla Al Sharm | Saudi Arabia

Dr. Abdulla Al Sharm
Director of Comprehensive Cancer Center
Dr. Abdullah Alsharm is the Director of comprehensive cancer center in King Fahad medical City, Assistant professor in King Saud bin Abdulaziz University for health science and Princess Norah University. Consultant medical oncology at comprehensive cancer center King Fahad Medical City, head of Scientific Committees in Saudi cancer institute and leader of cancer care in ministry of health , graduate from Queens University, Ontario, Canada in 2010, and medical oncology fellowship in gastrointestinal and genitourinary oncology from Queens University in 2011
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Dr. Syed Tirmazy | United Arab Emirates

Dr. Syed Tirmazy
Consultant Clinical Oncologist
"Dr Syed Hammad Tirmazy is a Consultant Clinical Oncologist and Head of Oncology at Dubai Hospital, DHA. He has substantive experience in managing adult solid cancers and has been involved in multiple international clinical trials. Before moving to Dubai in 2016, he was working as Consultant Clinical Oncologist in west midlands region UK. After completing his graduation, he moved to UK in 2003, he initially completed internal medicine training and MRCP and subsequently attained training in Clinical Oncology and worked in internationally renowned oncology centers in UK including Queen Elizabeth Hospital Birmingham. He completed Master’s in Clinical Oncology from university of Birmingham, FRCR Clinical Oncology from RCR London and has CCT in Clinical Oncology. He also attained FRCP Glasgow. "
Sessions by this speaker
Sunday, 2022-11-27
Session 4: Genitourinary malignancies II - Kidney & Bladder Cancers
11:00 - 14:00
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Prof. Rob Jones | United Kingdom

Prof. Rob Jones
Director, CRUK Clinical Trials Unit
Professor Jones is Director, CRUK Clinical Trials Unit, Beatson West of Scotland Cancer Centre. After undergraduate training at the Universities of Oxford and Edinburgh, Rob moved to Glasgow to train in internal medicine and then Medical Oncology. He completed PhD in the Frame Lab at the Beatson Institute for Cancer research, where he studied the role of Src kinase in metastatic progression. From 2003 to 2005 he was seconded to the department of Experimental (Discovery) Medicine at Alderley Park (AstraZeneca plc) where he provided translational medicine input to a number of early oncology projects in the invasion and metastasis biological effect area.
Lectures by this speaker
Sunday, 2022-11-27
Triple combination therapy is the recommended option for all patients with mCSPC- AGAINST
09:30 - 09:50
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Metastatic Renal Cell Carcinoma- Challenges in First-line Decision Making for Metastatic Clear Cell RCC
11:00 - 11:20
Sunday, 2022-11-27
Padcev® - Evolving landscape in the management of La/mUC - Supported by Astellas
12:30 - 12:50
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Prof. Syed Hussain | United Kingdom

Prof. Syed Hussain
Professor and Consultant in Medical Oncology
"Professor Hussain graduated from Dow Medical College Karachi in 1994. He completed his general medical professional training in UK. He did his Doctorate in Oncology from University of Birmingham. He then completed his Medical oncology training in Birmingham, United Kingdom and received his certification and specialist registration in Medical oncology. Professor Hussain is Professor and Consultant in Medical Oncology at the University of Sheffield and Sheffield Teaching Hospitals NHS Trust. His major areas of interest are management of urological cancers, clinical trials, early drug development and translational medicine. He has set up large number of clinical trials from early phase to late phase studies during his career. His work on organ preservation in bladder cancer moved all the way from an early phase I study (Hussain et al Annals of Oncology 2001) to phase II efficacy study (Hussain et al BJC 2004) that led to a Cancer Research UK funded study BC2001 trial that was reported in New England Journal of Medicine (James, Hussain, Hall et al April 2012). This study has now changed the standard of care for patients with muscle invasive bladder cancer opting for organ preservation treatment. Professor Hussain is principal investigator of number of studies in urological cancers. He is a chief investigator of a national randomised placebo-controlled phase II neo-adjuvant study in muscle invasive bladder cancer. He served as chief investigator of various early phase trials, and translational studies. Professor Hussain has authored over 105 peer-reviewed publications including 4 book chapters in textbooks of oncology. His Google scholar H-index is 37 with over 8300 citations. He has published in high impact journals including New England Journal of medicine, Lancet, Lancet Oncology, JAMA, JAMA Oncology, Journal of Clinical oncology, European Urology, Annals of Oncology, Nature communications, Clinical Cancer Research, British journal of Cancer. He has been an invited speaker to number of national and international meetings. Professor Hussain has secured funding of over 10 million pounds from funding bodies. "
Lectures by this speaker
Friday, 2022-11-25
Plenary 1: Future of Precision Oncology
08:40 - 09:00
Friday, 2022-11-25
Panel Discussion
09:40 - 10:00
Sunday, 2022-11-27
Looking in to the Future of Treatment for Advanced Urothelial Cancers
11:50 - 12:10
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Dr. Brian Chaplin | United Kingdom

Dr. Brian Chaplin
Consultant Urologist
Mr Chaplin is a consultant urological surgeon; he has worked at James Cook, Middlesbrough and North Tees, Stockton hospitals since April 2011. He was a consultant from 2006-2011 at Bradford Teaching Hospitals and from 2004 to 2006 at Erasmus Medical Centre, Rotterdam, the Netherlands. Mr Chaplin has a special interest in oncological urology. He is especially interested in bladder, prostate and renal cancer. He regularly performs radical surgery for cancer using open and laparoscopic techniques. He has a specific interest in robotic minimally invasive surgery and has been involved in the implementation of the robot for robotic cystectomy since the first case done at James Cook in February 2015. He regularly performs robotic and open radical cystectomies, robotic prostatectomies, open and laparoscopic nephrectomies and nephroureterectomies. He contributes to national audit and research trials. He has presented posters and research data at national and international conferences. He was appointed in April 2017 as multi-disciplinary team lead for the urology cancer centre at James Cook.
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Surgery
12:10 - 12:30
Dr. Jawaher Ali Ansari | United Arab Emirates

Dr. Jawaher Ali Ansari
Acting Chief, Oncology Clinic
Dr Jawaher Ansari completed his Clinical Oncology specialist training in Birmingham, UK and worked as a Consultant at the Beatson Cancer Centre in Glasgow, the second largest cancer center in the UK, prior to moving to the Middle East. Dr Ansari has been a principal investigator for several international clinical trials and has authored several peer-reviewed publications and textbook chapters. He has a specialist interest in Urology, Breast and Lung cancers.
Sessions by this speaker
Friday, 2022-11-25
Scientific Committee
00:00 - 23:55
Friday, 2022-11-25
Organizing Committee
00:00 - 23:55
Friday, 2022-11-25
Session 1 Plenary
08:30 - 11:00
Friday, 2022-11-25
Session 6: Abstract presentations
15:40 - 16:50
Sunday, 2022-11-27
Session 2: Genitourinary malignancies- I
08:30 - 11:00
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Lectures by this speaker
Friday, 2022-11-25
Panel Discussion
09:40 - 10:00
Sunday, 2022-11-27
Welcome Note
08:30 - 08:32
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Intensifying Therapy Earlier in the Disease Course , Are We Doing Enough to Improve Outcomes? - Supported by Bayer
10:00 - 10:20
Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen
10:20 - 10:40
Sunday, 2022-11-27
Padcev® - Evolving landscape in the management of La/mUC - Supported by Astellas
12:30 - 12:50
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Sunday, 2022-11-27
Updates on the Management of mRCC and Role of Cabozantinib in the 1st line Treatment - Supported by IPSEN
16:25 - 16:45
Friday, 2022-11-25
30 years of Innovation & commitment to enhancing patient experience- Neulastim Onpro - Supported by KyowaKirin
15:40 - 15:50
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
Dr. Aftab Ahmed Bhatti | United Arab Emirates

Dr. Aftab Ahmed Bhatti
Consultant Physician, Urology Clinic
Dr Aftab Ahmad Bhatti has recently joined Tawam Hospital as a Consultant Urological Surgeon, after working in the United Kingdom for more than 25 years. The main focus of his work is Urological Oncology, Minimally Invasive Robotic Surgery and Laparoscopic surgery. Dr Aftab A Bhatti graduated from the University of Punjab, Rawalpindi Medical College, Pakistan. He completed his higher urological training from the Northern Deanery, Newcastle upon Tyne, UK. Dr Aftab Bhatti has published over 40 peer reviewed publications and his area of research interest includes kidney and prostate cancer. the area of his interest includes active surveillance for the low risk prostate cancer, surgical anatomy of prostate, refinements to surgical techniques for robotic assisted radical prostatectomy and surgical outcomes of the high risk prostate cancer and prognostic markers for the kidney cancer.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Sunday, 2022-11-27
Session 2: Genitourinary malignancies- I
08:30 - 11:00
Sunday, 2022-11-27
Session 4: Genitourinary malignancies II - Kidney & Bladder Cancers
11:00 - 14:00
Lectures by this speaker
Sunday, 2022-11-27
Variations in Surgical Techniques during Robot Assisted Radical Prostatectomy an Individualised Approach
08:30 - 08:50
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
12:50 - 13:10
Lunch Break
13:00 - 14:00
Educational Sessions: Multi-Disciplinary Case Based Discussions
Dr. Jawaher Ali Ansari | United Arab Emirates

Dr. Jawaher Ali Ansari
Acting Chief, Oncology Clinic | United Arab Emirates
Dr Jawaher Ansari completed his Clinical Oncology specialist training in Birmingham, UK and worked as a Consultant at the Beatson Cancer Centre in Glasgow, the second largest cancer center in the UK, prior to moving to the Middle East. Dr Ansari has been a principal investigator for several international clinical trials and has authored several peer-reviewed publications and textbook chapters. He has a specialist interest in Urology, Breast and Lung cancers.
Sessions by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Lectures by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Chairperson:
Dr. Emad Dawoud | United Arab Emirates

Dr. Emad Dawoud
Consultant Physician, Oncology Clinic | United Arab Emirates
Dr. Emad Dawoud is a Consultant Medical Oncologist in Oncology department at Tawam hospital UAE, and Assistant professor of clinical oncology in Al Azhar University Cairo, Egypt. Dr. Dawoud has been principal investigator and co- investigator for more than 50 clinical trials and abstract published per reviewed journals and he is a member of various associations such as ASCO, ESMO, ESTRO.
Sessions by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Lectures by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Chairperson:
Dr. Nouri Bennini | United Arab Emirates

Dr. Nouri Bennini
Consultant Physician, Oncology Clinic | United Arab Emirates
Dr.Nouri Bennini is a Consultant Physician, Oncology Clinic at Tawam Hospital.
Sessions by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Lectures by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Thursday,
-
Case Presentation Lung Cancer
Prof. Abdul Rahman Jazieh | USA

Prof. Abdul Rahman Jazieh
Director of Innovations and Research and Director of International Program
"Director of Innovations and Research and Director of International Program at Cincinnati Cancer Advisors, Cincinnati, OH, USA. Editor in Chief, Global Journal on Quality and Safety in Healthcare. Former Chairman and Professor, Department of Oncology and a Professor at King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. Former Professor and Chief of Hematology Oncology Division at University of Cincinnati. Founded the MENA-NCCN Collaborating Center (KSA) and the Association of VA Hematology Oncology (www.avaho.org) (USA). Specialized in hematology, and oncology with master’s Degree in public health in health education and communication. He published more than 100 articles, books, and book chapters. Dr. Jazieh won multiple honors including Proclamation to the City of Cincinnati, naming a day in the City as Dr. Abdul Rahman Jazieh Day in 2006 and Special Recognition from NCCN as Global Partner in Cancer Care 2018. "
Sessions by this speaker
Saturday, 2022-11-26
Session 7: Lung Cancer Session
15:40 - 17:30
Lectures by this speaker
Saturday, 2022-11-26
Controversies in Stage III NSCLC Management
14:20 - 14:40
Saturday, 2022-11-26
Panel Discussion and Q&A’s
15:00 - 15:10
Saturday, 2022-11-26
Voting + Panel discussion
17:00 - 17:10
Sunday, 2022-11-27
Case Presentation Lung Cancer
14:00 - 14:45

Dr. Ignacio Gil-Bazo
Head of the Department of Oncology
"Prof. Gil-Bazo is the Head of the Department of Oncology and Scientific Director of the Valencian Institute of Oncology (IVO) in the city of Valencia, Spain. He has previously served as Chairman of the Department of Oncology at the University of Navarra, in Pamplona, Spain. In addition, he is Associate Professor of Medicine at the Department of Oncology at the University of Navarra School of Medicine and Director of the New Therapeutic Targets Laboratory of the Program in Solid Tumors at the Center for Applied Medical Research (CIMA). Prof. Gil-Bazo is a Medical Oncologist with expertise in Thoracic Oncology, Translational Research in Oncology and Clinical Investigation. The Valencian Institute of Oncology (IVO), an OECI accredited Cancer Center, is a nationally and internationally renowned institution, the largest and most prestigious private cancer center in Spain."
Lectures by this speaker
Saturday, 2022-11-26
Dual checkpoint blockade + chemotherapy is the preferred option?
16:40 - 17:00
Saturday, 2022-11-26
Voting + Panel discussion
17:00 - 17:10
Sunday, 2022-11-27
Case Presentation Lung Cancer
14:00 - 14:45
Dr. Asif Quadri | United Arab Emirates

Dr. Asif Quadri
Consultant Anatomical and Cyto-pathologist
"Dr. Asif Quadri is a Consultant Anatomical and Cyto-pathologist, who joined NRL, after working as Consultant and Chief of Anatomical Pathology at Tawam Hospital, the Regional Cancer Centre in UAE for seven years. Prior to that, he worked as a Consultant Anatomical Pathologist for five years at City Hospital, Sandwell & West Birmingham NHS Trust, UK. Dr. Quadri’s special interests include biomarkers, gynecological pathology, breast pathology, lung tumors, genitourinary pathology, and soft tissue tumors. After completing his medical degree at the College of Medicine, the University of Baghdad in Iraq. Dr. Quadri pursued his pathology residency training in the UK. He was awarded a Certificate of Completion in Specialist Training (CCT) for Anatomical Pathology & Cytopathology from the Postgraduate Medical and Education Training Board and General Medical Council in the UK and a Fellow of the Royal College of Pathologists, London. His interest in Medical Education earned him a Postgraduate Certificate in Medical Education from the University of Staffordshire, also in the UK. Dr. Quadri is a College of American Pathologists (CAP) accreditation inspection team member. He is also a regional expert and trainer for companion diagnostic immunochemistry for PDL1 biomarker clones. He has been published in numerous professional journals and frequently presents cases and papers at local and regional meetings. "
Lectures by this speaker
Sunday, 2022-11-27
Case Presentation Lung Cancer
14:00 - 14:45
Sunday, 2022-11-27
Case Presentation Breast Cancer
14:45 - 15:30
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Dr. Hussain Aby Ali | United Arab Emirates

Dr. Hussain Aby Ali
Consultant Radiologist
Dr. Hussain Aby Ali is consultant Radiologist at Tawam Hospital since 2016 - Chief of diagnostic radiology 2022-till present - Physician lead 2020-2022 - Deputy Chair of radiology dep 2018-2020 - Chair of head and neck MDT 2020-till present Graduated from Jordan University of Science and Technology as a Doctor of medicine –Jordan, 2006 Master degree from Jordan University of Science and Technology in diagnostic radiology 2011 Arab Board in radiology and medical imaging 2012 Oncology imaging fellowship from King Hussein Cancer Center (KHCC) 2013 Specialist Radiologist in KHCC 2013-2014 Consultant Radiologist in KHCC 2014-2016 with interventional experience for 1 year. Joined Tawam hospital in 2016 as head of CT section and becomes a deputy in 2018-2020. In 2020, becomes the chair of head and neck MDT meeting till present. In 2022, becomes the chief of diagnostic radiology till present. In 2020, becomes the main radiologist covering the chest MDT. His main interest is oncology imaging, chest, neuroradiology and head and neck radiology.
Lectures by this speaker
Sunday, 2022-11-27
Case Presentation Lung Cancer
14:00 - 14:45
Dr. Omran El Koha | United Arab Emirates

Dr. Omran El Koha
Consultant Radiation /Clinical Oncologist
Dr. Omran is an experienced clinical oncologist with a demonstrated history of working in the medical and radiation oncology p . Skilled in Clinical Research, Medical Education, Strategic Planning. Strong education professional with a Master's Degree focused in Health research ethics
Sessions by this speaker
Sunday, 2022-11-27
Session 1: Paediatric Oncology
08:30 - 11:00
Saturday, 2022-11-26
Session 7: Lung Cancer Session
15:40 - 17:30
Lectures by this speaker
Saturday, 2022-11-26
Voting + Panel discussion
17:00 - 17:10
Sunday, 2022-11-27
Case Presentation Lung Cancer
14:00 - 14:45
Sunday, 2022-11-27
Panel Discussion and Q&A’s
10:10 - 10:30
Dr. Edward Black | United Arab Emirates

Dr. Edward Black
Consultant - Thoracic Surgery
Dr Edward Black graduated from Guy’s Medical School, London in 1992. He trained in Cardiothoracic Surgery in Oxford, Leicester, Nottingham, Sheffield and Edinburgh. He was awarded Certificate of Completion of Specialist Training in Cardiothoracic Surgery in 2005. He is a Fellow of the Royal College of Surgeons of England in General Surgery and Cardiothoracic Surgery. He was appointed Consultant Thoracic Surgeon in Nottingham University Hospitals in 2006, Oxford University Hospitals in 2009 and SEHA in 2014. He currently works in SEHA-Mayo Clinic joint venture at SSMC Abu Dhabi and is Associate Professor at Khalifa University Medical School Abu Dhabi. He is Vice President of the Thoracic Surgery Group of the Emirates Respiratory Society.
Lectures by this speaker
Sunday, 2022-11-27
Case Presentation Lung Cancer
14:00 - 14:45
Dr. Emad Dawoud | United Arab Emirates

Dr. Emad Dawoud
Consultant Physician, Oncology Clinic
Dr. Emad Dawoud is a Consultant Medical Oncologist in Oncology department at Tawam hospital UAE, and Assistant professor of clinical oncology in Al Azhar University Cairo, Egypt. Dr. Dawoud has been principal investigator and co- investigator for more than 50 clinical trials and abstract published per reviewed journals and he is a member of various associations such as ASCO, ESMO, ESTRO.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Friday, 2022-11-25
Session 3: Gynaecological cancers
11:20 - 14:00
Friday, 2022-11-25
Session 5: Gynaecological Cancers
14:00 - 15:40
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Saturday, 2022-11-26
Session 1: Early Breast Cancer Session
08:30 - 11:00
Lectures by this speaker
Friday, 2022-11-25
Management of endometrial cancer in the molecular era
15:40 - 16:00
Friday, 2022-11-25
Panel Discussion- Q&A
15:00 - 15:20
Friday, 2022-11-25
Endometrial Cancer - Case Based Discussion
12:00 - 12:30
Friday, 2022-11-25
Panel Discussion
12:30 - 12:40
Friday, 2022-11-25
Panel Discussion- Q&A
16:20 - 16:30
Saturday, 2022-11-26
Recent Advances in Systemic Therapy in Resected Lung Cancer - Supported by Roche
14:40 - 15:00
Saturday, 2022-11-26
Panel Discussion and Q&A’s
15:00 - 15:10
Sunday, 2022-11-27
Panel Discussion and Q & A
12:40 - 13:00
Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen
10:20 - 10:40
Sunday, 2022-11-27
Case Presentation Lung Cancer
14:00 - 14:45
Sunday, 2022-11-27
Optimizing the 1st line treatment in mCRC - Supported by Merck
12:00 - 12:20
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
Saturday, 2022-11-26
Early Breast Cancer and the Use of Abemacilcib to Prevent Recurrence in Patients with HR+, HER2- with High Risk of Recurrence - Supported by Lilly
09:50 - 10:10
14:00 - 14:45
Case Presentation Breast Cancer

Dr. Anwar Al Nouri
Oncologist
Dr. Anwar Al Nouri is an oncologist at Kuwait Cancer Control Centre
Lectures by this speaker
Saturday, 2022-11-26
Palbociclib-based therapy is the preferred first-line option
11:10 - 11:20
Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC
11:30 - 11:40
Sunday, 2022-11-27
Case Presentation Breast Cancer
14:45 - 15:30
Dr. Syed Mansoor Hasnain | United Arab Emirates

Dr. Syed Mansoor Hasnain
Consultant Radiation Oncologist
"Dr. Syed Mansoor Hasnain is working in Tawam Hospital, Alain, UAE as Consultant Radiation Oncologist. He joined Tawam Hospital in 2009. He initially trained as surgeon and did fellowship in surgery ,FRCS(Glasg) from Royal College Of Physicians and Surgeons Of Glasgow in 2000. In 2001 he started his career and specialist registrar Training in radiation Oncology under supervision of Faculty of Radiology, The Royal College Of Surgeons In Ireland in Saint Luke’s Hospital. He passed FRCR part 1 from Royal College of Radiologists, London U.K. He did fellowship in radiotherapy ‘FFR RCSI’ from Faculty of Radiology , Royal College Of Surgeons In Ireland in 2007. In 2010 he got CCST 'completion of certified specialist training certificate’ from Faculty of Radiology, The Royal College Of Surgeons In Ireland and entry in to specialist register in Medical Council of Ireland. In Tawam in early 2011, Dr. Mansoor successfully led the commissioning and clinical use of the HiArt TomoTherapy system with IMRT & IGRT, one and only in UAE. . In 2013 Dr. Mansoor chaired RapidArc committee, making sure smooth and swift implementation of RapidArc technology with IMRT & IGRT capability in Tawam. In 2015 Dr. Mansoor was appointed as Adjunct Assistant Professor in College of Medicine and health Sciences in UAE University. . In 2018 as lead radiation oncologist, he successfully led the QUATRO certification of the radiotherapy department by IAEA. He is clinical lead Radiation oncologist for Lymphoma, Sarcoma, Urology & GI tumours. "
Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s
10:30 - 10:40
Saturday, 2022-11-26
CNS Lymphoma debate There is a role of radiotherapy in primary CNS Lymphoma
08:50 - 09:10
Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions
16:00 - 16:40
Sunday, 2022-11-27
Case Presentation Breast Cancer
14:45 - 15:30
Dr. Asif Quadri | United Arab Emirates

Dr. Asif Quadri
Consultant Anatomical and Cyto-pathologist
"Dr. Asif Quadri is a Consultant Anatomical and Cyto-pathologist, who joined NRL, after working as Consultant and Chief of Anatomical Pathology at Tawam Hospital, the Regional Cancer Centre in UAE for seven years. Prior to that, he worked as a Consultant Anatomical Pathologist for five years at City Hospital, Sandwell & West Birmingham NHS Trust, UK. Dr. Quadri’s special interests include biomarkers, gynecological pathology, breast pathology, lung tumors, genitourinary pathology, and soft tissue tumors. After completing his medical degree at the College of Medicine, the University of Baghdad in Iraq. Dr. Quadri pursued his pathology residency training in the UK. He was awarded a Certificate of Completion in Specialist Training (CCT) for Anatomical Pathology & Cytopathology from the Postgraduate Medical and Education Training Board and General Medical Council in the UK and a Fellow of the Royal College of Pathologists, London. His interest in Medical Education earned him a Postgraduate Certificate in Medical Education from the University of Staffordshire, also in the UK. Dr. Quadri is a College of American Pathologists (CAP) accreditation inspection team member. He is also a regional expert and trainer for companion diagnostic immunochemistry for PDL1 biomarker clones. He has been published in numerous professional journals and frequently presents cases and papers at local and regional meetings. "
Lectures by this speaker
Sunday, 2022-11-27
Case Presentation Lung Cancer
14:00 - 14:45
Sunday, 2022-11-27
Case Presentation Breast Cancer
14:45 - 15:30
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Dr. Abdul Ghani | United Arab Emirates

Dr. Abdul Ghani
Consultant Pathologist
Abdulghani Elomami consultant pathologist at Tawam Hospital, Al Ain, UAE since 2015 to date and Adjunct assistant professor at College of Medicine and Health sciences, United Arab Emirate University since 2016 to date. He was consultant pathologist at Red Deer Hospital, Alberta Health services from 2009 to 2015. He has done his residency training at the University of British Columbia, Vancouver-Canada in 2004 and passed FRCPC exam in 2008, after that he did one year fellowship at Vancouver General hospital and British Columbia Cancer Agency. He received Master degree in April 2000 after spent 4 years of training at Pathology Department, Garyounis University, Benghazi-Libya, passed the exams and prepared thesis “The Proliferation markers in serous tumors of ovary”. He worked as assistant professor for third year medical student at Medical College, Garyounis University and as histopathology staff in Central lab at the university from 2000 till 2003. He received his medical degree from Faculty of Medicine at AL-Arab Medical University - Libya in 1994
Lectures by this speaker
Sunday, 2022-11-27
Case Presentation Breast Cancer
14:45 - 15:30
Dr. Tarek Benashur | United Arab Emirates

Dr. Tarek Benashur
Consultant Breast Imaging Radiologist
Tarek Benashur, Tripoli, Norht Africa Consultant Breast imaging radiologist German Facharzt 2001 EDBI 2015 MBBS 1987 Head of the radiology in Breast care Center Tawam H. Al Ain, UAE
Lectures by this speaker
Sunday, 2022-11-27
Case Presentation Breast Cancer
14:45 - 15:30
Dr. Dorai Ramanathan | United Arab Emirates

Dr. Dorai Ramanathan
Consultant Oncologist
Dr. Dorai Ramanathan is a highly qualified Oncologist from the United Kingdom with over 13 years’ experience in managing adult cancer patients alone. His expertise is both in Chemotherapy and Radiotherapy for all adult solid tumors. His sites of special interest are Breast, Lung, Gynaecological and Colon cancer.
Lectures by this speaker
Saturday, 2022-11-26
Update on strategies to improve outcomes in early triple negative Breast cancer
08:50 - 09:10
Sunday, 2022-11-27
Case Presentation Breast Cancer
14:45 - 15:30
Dr. Ernest Johan Luiten | United Arab Emirates

Dr. Ernest Johan Luiten
Chief of Breast Cancer Center
Chief of Breast Cancer Center- Tawam Hospital
Sessions by this speaker
Friday, 2022-11-25
Scientific Committee
00:00 - 23:55
Saturday, 2022-11-26
Session 3: Advanced Breast Cancer Session
11:00 - 14:00
Lectures by this speaker
Sunday, 2022-11-27
Case Presentation Breast Cancer
14:45 - 15:30
Dr. Nouri Bennini | United Arab Emirates

Dr. Nouri Bennini
Consultant Physician, Oncology Clinic
Dr.Nouri Bennini is a Consultant Physician, Oncology Clinic at Tawam Hospital.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Saturday, 2022-11-26
Session 1: Early Breast Cancer Session
08:30 - 11:00
Sunday, 2022-11-27
Session 5: Gastrointestinal Session
14:00 - 16:40
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s
10:10 - 10:30
Saturday, 2022-11-26
Beyond Covid 19 Vaccination : Evusheld (Tixagevimab and Cilgevimab ) for the Prevention and Treatment of Covid 19 among the High Risk Patients - Supported by AstraZeneca
15:10 - 15:30
Sunday, 2022-11-27
Panel Discussion and Q&A’s
15:20 - 15:30
Sunday, 2022-11-27
Dual Immunotherapy Approach in 1L RCC Treatment - Supported by BMS
11:20 - 11:50
Sunday, 2022-11-27
Case Presentation Breast Cancer
14:45 - 15:30
Sunday, 2022-11-27
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly
12:20 - 12:40
14:45 - 15:30
COFFEE BREAK
15:30 - 15:40
Bladder Cancer Case Based Discussion
Dr. Abdulla Al Sharm | Saudi Arabia

Dr. Abdulla Al Sharm
Director of Comprehensive Cancer Center
Dr. Abdullah Alsharm is the Director of comprehensive cancer center in King Fahad medical City, Assistant professor in King Saud bin Abdulaziz University for health science and Princess Norah University. Consultant medical oncology at comprehensive cancer center King Fahad Medical City, head of Scientific Committees in Saudi cancer institute and leader of cancer care in ministry of health , graduate from Queens University, Ontario, Canada in 2010, and medical oncology fellowship in gastrointestinal and genitourinary oncology from Queens University in 2011
Lectures by this speaker
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25

Dr. Mohammed Ashour
Consultant Medical Oncologist
Consultant Medical oncologist Kuwait cancer control center. Prof. Clinical Oncology Alzhar University. Cancer research diploma Harvard University. Member of ASCO and ESMO. Interested in GU&GY malignancy. Has many publications in peer review journal.
Lectures by this speaker
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Dr. Adnan Hussain | Saudi Arabia

Dr. Adnan Hussain
Consultant Medical Oncologist
Dr Adnan Hussain works as a Consultant Medical Oncologist at King Faisal Specialist Hospital and Research Center, Jeddah. He has special interest in GI and GU malignancies He did his M.B.B.S from Dow Medical University, Karachi in 2001 after which he moved to UK in 2003 for further training. He did his core medical training and then specialist training in United Kingdom at Belfast Health and Social Care trust followed by which he joined Worcestershire Royal Hospital as a Consultant Medical Oncologist. He moved to KSA in 2015 and currently works at King Faisal Specialist Hospital and Research Center, Jeddah.
Lectures by this speaker
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Dr. Hidayath Ansari | United Arab Emirates

Dr. Hidayath Ansari
Consultant Radiologist
"Dr. Hidayath Ali Ansari is Consultant Radiologist, Chief of Nuclear Medicine at the Imaging Institute of Cleveland Clinic Abu Dhabi and Medical Director of Cleveland Clinic Abu Dhabi ( AlAin Branch). Prior to his career in UAE; Dr. Ansari worked as a Consultant Radiologist and Clinical Director for the Department of Radiology at the University Hospitals of Morecambe Bay (NHS) Trust in Lancaster, UK and as Chair of the Radiology, Lancashire Cancer Network. He completed his residency and Fellowships in Specialist Radiology Training at Manchester with PET-CT fellowship at the University Hospital Zurich in Switzerland. His areas of Specialist Expertise include PETCT, Nuclear medicine, CT Colonography and MR Enterography. He has worked with his team to establish Cardiac blood flow quantification, American College of Radiology accreditation, contrast enhanced PETCT and new isotope services including DAT Imaging for Parkinsonism, Sentinel node mapping and hybrid imaging amongst few recent achievements and are working towards establishing Gallium PETCT for prostate and Neuro endocrine tumors. He has been recently awarded Clinical Excellence award for 2019 for recognition of his contribution. He is a fellow of Royal College of Radiologists, actively involved in education and research. He received Four NHS Clinical Excellence Awards from University Hospitals Morecambe Bay NHS in-between 2009 and 2014 in recognition of exceptional contributions to patient safety, quality of clinical care and education. "
Lectures by this speaker
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25

Dr. Nadeem Pervez
Radiation Oncologist
"Dr. Nadeem Pervez qualified in Radiation Oncologist from Ireland and Canada. He worked in Ireland, Canada and Middle East at various academic levels. He served as radiation oncologist at Cross Cancer Institute and Associate Professor at University of Alberta, Edmonton, Alberta, Canada. His clinical work includes treating cancer of various sites with emphasis on breast and prostate cancer. He was a prominent member of Prostate Cancer Brachytherapy seed implantation treatment in Canada. He is initiating Prostate Brachytherapy treatment in the Middle East. He co-chaired breast cancer group in Alberta and contributed to Alberta Breast Cancer Treatment guidelines. He was involved in invention of newer radiotherapy machines. Nadeem was actively involved in contributing to Resident Training program and Clinical Research Fellowship program in Radiation Oncology at the University of Alberta, Canada. He was awarded best teacher award from residents to acknowledge his contributions. He oversees research projects from international fellows. His residents and fellows later appointed at key academic, clinical and leadership positions across world. He was invited as scientific speaker in multiple countries. Nadeem is actively involved in clinical research. He was able to secure multiple competitive research grants from awarding agencies. He was leading investigator initiated studies and involved in multi-institutional cooperative group studies. He published multiple research articles in reputed journals. He served in institutional ethics committees, research funds granting agencies, medical student selection committees, oncology conference scientific committee and peer-reviewed several Oncology journals. He is founding member in establishing Middle East Society of Therapeutic Radiation Oncology (MESTRO). "
Lectures by this speaker
Saturday, 2022-11-26
Advances in Prostate Radiotherapy
14:40 - 15:00
Saturday, 2022-11-26
Panel Discussion
15:20 - 15:30
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Dr. Sulaman Magdub | United Arab Emirates

Dr. Sulaman Magdub
Histopathology Consultant
Acting chief of Hisopatology at Tawam Hospital. Experienced Consultant with a history of working in the hospital & health care industry. Skilled in Medical Diagnostics, Healthcare Information Technology (HIT), Healthcare Management, Healthcare, and Clinical Research. Strong consulting professional with a Doctor of Medicine - MD focused in Medicine from Al Arab Medical University.
Lectures by this speaker
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25

Dr. Jamila Riromar
Consultant Medical Oncologist
"Dr Jamila Rir Omar is a consultant medical oncologist with special inters in improving metastatic cancer patient’s outcomes. She has joined genitourinary + gynecology subspeciality, in National Oncology Center Muscat, Sultanate of Oman since September 2019. She has obtained 2 years fellowship program in Genitourinary medical oncology from university of Toronto Canada, May 2017- June 2019. She has completed 5 years speciality residency program in medical oncology from university Claude Bernard Lyon 1, republic of France with DES French board in medical oncology. She completed internal medicine training program from Oman Medical Speciality Board (OMSB) in august 2009 with MRCP-UK February 2009."
Lectures by this speaker
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Dr. Asif Quadri | United Arab Emirates

Dr. Asif Quadri
Consultant Anatomical and Cyto-pathologist
"Dr. Asif Quadri is a Consultant Anatomical and Cyto-pathologist, who joined NRL, after working as Consultant and Chief of Anatomical Pathology at Tawam Hospital, the Regional Cancer Centre in UAE for seven years. Prior to that, he worked as a Consultant Anatomical Pathologist for five years at City Hospital, Sandwell & West Birmingham NHS Trust, UK. Dr. Quadri’s special interests include biomarkers, gynecological pathology, breast pathology, lung tumors, genitourinary pathology, and soft tissue tumors. After completing his medical degree at the College of Medicine, the University of Baghdad in Iraq. Dr. Quadri pursued his pathology residency training in the UK. He was awarded a Certificate of Completion in Specialist Training (CCT) for Anatomical Pathology & Cytopathology from the Postgraduate Medical and Education Training Board and General Medical Council in the UK and a Fellow of the Royal College of Pathologists, London. His interest in Medical Education earned him a Postgraduate Certificate in Medical Education from the University of Staffordshire, also in the UK. Dr. Quadri is a College of American Pathologists (CAP) accreditation inspection team member. He is also a regional expert and trainer for companion diagnostic immunochemistry for PDL1 biomarker clones. He has been published in numerous professional journals and frequently presents cases and papers at local and regional meetings. "
Lectures by this speaker
Sunday, 2022-11-27
Case Presentation Lung Cancer
14:00 - 14:45
Sunday, 2022-11-27
Case Presentation Breast Cancer
14:45 - 15:30
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Dr. Jawaher Ali Ansari | United Arab Emirates

Dr. Jawaher Ali Ansari
Acting Chief, Oncology Clinic
Dr Jawaher Ansari completed his Clinical Oncology specialist training in Birmingham, UK and worked as a Consultant at the Beatson Cancer Centre in Glasgow, the second largest cancer center in the UK, prior to moving to the Middle East. Dr Ansari has been a principal investigator for several international clinical trials and has authored several peer-reviewed publications and textbook chapters. He has a specialist interest in Urology, Breast and Lung cancers.
Sessions by this speaker
Friday, 2022-11-25
Scientific Committee
00:00 - 23:55
Friday, 2022-11-25
Organizing Committee
00:00 - 23:55
Friday, 2022-11-25
Session 1 Plenary
08:30 - 11:00
Friday, 2022-11-25
Session 6: Abstract presentations
15:40 - 16:50
Sunday, 2022-11-27
Session 2: Genitourinary malignancies- I
08:30 - 11:00
Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions
14:00 - 16:50
Lectures by this speaker
Friday, 2022-11-25
Panel Discussion
09:40 - 10:00
Sunday, 2022-11-27
Welcome Note
08:30 - 08:32
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Intensifying Therapy Earlier in the Disease Course , Are We Doing Enough to Improve Outcomes? - Supported by Bayer
10:00 - 10:20
Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen
10:20 - 10:40
Sunday, 2022-11-27
Padcev® - Evolving landscape in the management of La/mUC - Supported by Astellas
12:30 - 12:50
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
Sunday, 2022-11-27
Updates on the Management of mRCC and Role of Cabozantinib in the 1st line Treatment - Supported by IPSEN
16:25 - 16:45
Friday, 2022-11-25
30 years of Innovation & commitment to enhancing patient experience- Neulastim Onpro - Supported by KyowaKirin
15:40 - 15:50
Sunday, 2022-11-27
Panel Discussion and Q & A
10:40 - 10:50
Dr. Aftab Ahmed Bhatti | United Arab Emirates

Dr. Aftab Ahmed Bhatti
Consultant Physician, Urology Clinic
Dr Aftab Ahmad Bhatti has recently joined Tawam Hospital as a Consultant Urological Surgeon, after working in the United Kingdom for more than 25 years. The main focus of his work is Urological Oncology, Minimally Invasive Robotic Surgery and Laparoscopic surgery. Dr Aftab A Bhatti graduated from the University of Punjab, Rawalpindi Medical College, Pakistan. He completed his higher urological training from the Northern Deanery, Newcastle upon Tyne, UK. Dr Aftab Bhatti has published over 40 peer reviewed publications and his area of research interest includes kidney and prostate cancer. the area of his interest includes active surveillance for the low risk prostate cancer, surgical anatomy of prostate, refinements to surgical techniques for robotic assisted radical prostatectomy and surgical outcomes of the high risk prostate cancer and prognostic markers for the kidney cancer.
Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee
00:00 - 23:55
Sunday, 2022-11-27
Session 2: Genitourinary malignancies- I
08:30 - 11:00
Sunday, 2022-11-27
Session 4: Genitourinary malignancies II - Kidney & Bladder Cancers
11:00 - 14:00
Lectures by this speaker
Sunday, 2022-11-27
Variations in Surgical Techniques during Robot Assisted Radical Prostatectomy an Individualised Approach
08:30 - 08:50
Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting
09:50 - 10:00
Sunday, 2022-11-27
Panel Discussion
12:50 - 13:10
Sunday, 2022-11-27
Bladder Cancer Case Based Discussion
15:40 - 16:25
15:40 - 16:25
Updates on the Management of mRCC and Role of Cabozantinib in the 1st line Treatment - Supported by IPSEN
Dr. Guillermo de Velasco | Spain

Dr. Guillermo de Velasco
Associate Professor in Hematology
"Guillermo de Velasco, MD PhD, is a medical oncologist with special interest in GU tumors. Dr. de Velasco received his medical degree from Complutense University, Madrid (Spain) in 2006. In 2011, Dr. de Velasco completed his residency training in Medical Oncology at the University Hospital 12 de Octubre. During the last two years of his fellowship, he also obtained a Master degree in Molecular Oncology at CNIO, Madrid (Spain). After finishing his Oncology fellowship in Spain, Dr. de Velasco was awarded with an ESMO fellowship to work in the Genitourinary Department at Cambridge University (UK)--nder the directorship of Professor Tim Eisen. While there, he also developed research in Christian Frezza’s Lab to explore metabolomics signatures in kidney cancer. In 2015, Dr. de Velasco was awarded with a SEOM fellowship to join the Dana-Farber/Harvard Cancer Center, as a research fellow with Professor Toni K. Choueiri, where he was involved in several clinical and translation investigations in the Genitourinary field. Dr. de Velasco is currently an independent clinical researcher and attending physician at University Hospital 12 de Octubre. His research focuses on understanding mechanism of response and resistance to different treatments in in renal cell carcinoma and other GU malignancies "
Lectures by this speaker
Sunday, 2022-11-27
Updates on the Management of mRCC and Role of Cabozantinib in the 1st line Treatment - Supported by IPSEN
16:25 - 16:45
Dr. Jawaher Ali Ansari | United Arab Emirates

Dr. Jawaher Ali Ansari
Acting Chief, Oncology Clinic
Dr Jawaher Ansari completed his Clinical Oncology specialist training in Birmingham, UK and worked as a Consultant at the Beatson Cancer Centre in Glasgow, the second largest cancer center in the UK, prior to moving to the Middle East. Dr Ansari has been a principal investigator for several international clinical trials and has authored several peer-reviewed publications and textbook chapters. He has a specialist interest in Urology, Breast and Lung cancers.